Document:

rsls_Ex10_32

		

			Exhibit 10.32

		

		
			 
		

		
			GUARANTEE AND COLLATERAL AGREEMENT
		

		
			dated as of March 25, 2020
		

		
			among
		

		
			RESHAPE LIFESCIENCES INC.
		

		
			and
		

		
			 
		

		
			RESHAPE MEDICAL LLC
		

		
			 
		

		
			as Grantors,
		

		
			 
		

		
			and
		

		
			ARMISTICE CAPITAL MASTER FUND LTD.,
		

		
			as Lender
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

		
			GUARANTEE AND COLLATERAL AGREEMENT
		

		
			Guarantee and Collateral Agreement, dated as of March 25, 2020 (this “Agreement”), made by each signatory hereto (together with any other Person that becomes a party hereto as provided herein,  (“Grantors”), in favor of Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (“Lender”).
		

		
			Lender has agreed to extend credit to ReShape Lifesciences Inc., a Delaware corporation (“Borrower”’) pursuant to the Credit Agreement (as defined below).  Borrower is affiliated with each other Grantor.  The proceeds of credit extended under the Credit Agreement will be used in part to enable Borrower to make valuable transfers to Grantors in connection with the operation of their respective businesses.  Borrower and the other Grantors are engaged in interrelated businesses, and each Grantor will derive substantial direct and/or indirect benefit from extensions of credit under the Credit Agreement.
		

		
			It is a condition precedent to Lender’s obligation to extend credit under the Credit Agreement that Grantors shall have executed and delivered this Agreement to Lender.
		

		
			In consideration of the premises and to induce Lender to enter into the Credit Agreement and to induce Lender to extend credit thereunder, each Grantor hereby agrees with Lender, as follows:
		

		
			1.Definitions.
		

		
			1.1Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement, and the following terms are used herein as defined in the UCC (as defined below): Accounts, Certificated Security, Chattel Paper, Commercial Tort Claims, Control, Deposit Accounts, Documents, Electronic Chattel Paper, Equipment, Farm Products, Goods, Health-Care-Insurance Receivables, Instruments, Inventory, Letter-of-Credit Rights and Supporting Obligations.  Unless otherwise expressly stated to the contrary herein, the interpretation of terms in this Agreement shall be governed by the rules set forth in Section 1.2 of the Credit Agreement.
		

		
			1.2When used herein the following terms shall have the following meanings:
		

		
			Agreement has the meaning set forth in the preamble hereto.
		

		
			Borrower has the meaning set forth in the preamble hereto.
		

		
			Borrower Obligations means all Obligations of Borrower.
		

		
			Collateral means (a) all of each Grantor’s right, title and interest in and to Accounts, Chattel Paper (including Electronic Chattel Paper), Deposit Accounts, Documents, Equipment, Farm Products, General Intangibles, Goods, Health-Care-Insurance Receivables, Instruments, Intellectual Property, Inventory, Investment Property, Letter-of-Credit Rights, Supporting Obligations, Identified Claims and other personal property, in each case whether now owned or at any time hereafter acquired or arising, (b) all books and records pertaining to any of the foregoing, (c) all Proceeds and products of any of the foregoing and (d) all collateral security and guarantees
		

		
			
		

		
			

		 

		

			 

		

		

			 

		

		

			 

		

		

		
			 
		

		
			given by any Person with respect to any of the foregoing; provided, that the Collateral (nor any defined term used in the definition thereof) shall not include the Excluded Property.  Where the context requires, terms relating to the Collateral or any part thereof, when used in relation to a Grantor, shall refer to such Grantor’s Collateral or the relevant part thereof.
		

		
			Copyrights means all copyrights arising under the laws of the United States, any other country or any political subdivision thereof, and any other rights in works of authorship whether registered or unregistered and whether published or unpublished, all registrations and recordings and tangible media thereof, and all applications in connection therewith, including all registrations and applications in the United States Copyright Office and any foreign copyright offices, and the right to obtain all renewals and extensions of any of the foregoing, along with any moral rights or any equivalent rights.
		

		
			Copyright Licenses means all written agreements naming any Grantor as licensor or licensee, granting any right under any Copyright, including the grant of rights to manufacture, reproduce, distribute, exploit and sell materials derived from any Copyright.
		

		
			Credit Agreement means the Credit Agreement of even date herewith between Borrower and Lender, as amended, supplemented, restated or otherwise modified from time to time.
		

		
			Excluded Property means, with respect to a Grantor, (a) motor vehicles and other assets subject to certificates of title, (b) “intent-to-use” Trademarks for which a statement of use has not been filed and accepted with the U.S.  Patent and Trademark Office and any other Intellectual Property if the grant of a Lien on or security interest in such Intellectual Property would result in the cancellation or voiding of such Intellectual Property, (c) any receivable paid into a Trust Account (as defined in the Credit Agreement) and the balance of any such Trust Account maintained by any Grantor for the benefit of an agency of the federal government of the United States of America, (d) Exempt Accounts (excluding accounts constituting Exempt Accounts pursuant to clause (a)(iv) of the definition thereof), (e) any assets owned by such Grantor that are subject to a purchase money security interest or a Capital Lease permitted under the Credit Agreement, but only to the extent that the agreements governing such purchase money security interest or Capital Lease prohibit the granting of other Liens in such assets and any necessary consent required for the granting of other Liens in such assets has not been obtained; (f) any property of the type expressly excluded from the definitions of Investment Property and Pledged Equity; (g) any item of General Intangibles that is now or hereafter held by such Grantor but only to the extent that such item of General Intangibles (or any agreement evidencing such item of General Intangibles) contains a term or is subject to a rule of law, statute or regulation that restricts, prohibits, or requires a consent (that has not been obtained) of a Person (other than such Grantor) to, the creation, attachment or perfection of the security interest granted herein, and any such restriction, prohibition and/or requirement of consent is effective and enforceable under applicable law and is not rendered ineffective by applicable law (including, without limitation, pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the UCC),  and (h) real property owned by any Grantor, interests in real property leases of any Grantor and any fixtures thereon;  provided,  however, that (x) Excluded Property shall not include any Proceeds of any item of General Intangibles or Proceeds of any other Excluded Property unless such Proceeds themselves constitute Excluded Property pursuant to clauses (a), (b), (c), (d), (e), (f), (g) or (h) above, and (y) any item of General Intangibles or other Excluded Property that at any time ceases to satisfy the criteria for Excluded
		

		
			
		

		
			

		 

		

			-3-

		

		

			 

		

		

		
			 
		

		
			Property (whether as a result of the applicable Grantor obtaining any necessary consent, any change in any rule of law, statute or regulation, or otherwise), shall no longer be Excluded Property.
		

		
			General Intangibles means all “general intangibles” as such term is defined in Section 9-102 of the UCC and, in any event, including with respect to any Grantor, all contracts, agreements, instruments and indentures in any form, and portions thereof, to which such Grantor is a party or under which such Grantor has any right, title or interest or to which such Grantor or any property of such Grantor is subject, as the same from time to time may be amended, supplemented or otherwise modified, including, without limitation, (a) all rights of such Grantor to receive moneys due and to become due to it thereunder or in connection therewith, (b) all rights of such Grantor to damages arising thereunder and (c) all rights of such Grantor to perform and to exercise all remedies thereunder.
		

		
			Grantors has the meaning set forth in the preamble hereto.
		

		
			Guarantor Obligations means, with respect to each Guarantor, all of such Guarantor’s Obligations.
		

		
			Guarantors means the collective reference to each Grantor other than Borrower.
		

		
			Identified Claims means the Commercial Tort Claims described on Schedule 7.
		

		
			Intellectual Property means the collective reference to all rights, priorities and privileges relating to intellectual property anywhere in the world, including Copyrights, Copyright Licenses, Patents, Patent Licenses, Trademarks and Trademark Licenses, and all rights to sue at law or in equity for any past, present or future infringement, misappropriation, dilution or other impairment thereof, including the right to receive all proceeds and damages therefrom, including,  but not limited to, Copyrights, Patents and Trademarks related to lap band and vest technology.
		

		
			Intercompany Note means any promissory note evidencing loans made by any Grantor to any other Grantor.
		

		
			Investment Property means the collective reference to (a) all “investment property” as such term is defined in Section 9-102 of the UCC (other than the equity interest of any Foreign Subsidiary or Excluded Foreign Holding Company excluded from the definition of Pledged Equity), (b) all “financial assets” as such term is defined in Section 8-102(a)(9) of the UCC, and (c) whether or not constituting “investment property” as so defined, all Pledged Notes and all Pledged Equity.
		

		
			Issuers means the collective reference to each issuer of any Investment Property which constitutes Collateral.
		

		
			Lender has the meaning set forth in the preamble hereto.
		

		
			Patents means (a) all letters patent of the United States, any other country or any political subdivision thereof or any international or regional body, all reissues, renewals and extensions thereof, (b) all applications for letters patent of the United States or any other country and all
		

		
			
		

		
			

		 

		

			-4-

		

		

			 

		

		

		
			 
		

		
			political subdivisions thereof or any international or regional bodies, continuations, divisionals and continuations-in-part thereof, and any patents maturing therefrom (c) the inventions disclosed or claimed therein, and (d) all rights to obtain any reissues or extensions of the foregoing.
		

		
			Patent Licenses means all written agreements providing for the grant by or to any Grantor of any right to make, manufacture, use, import, export, offer for sale or sell any invention covered in whole or in part by a Patent.
		

		
			Permitted Liens means the Liens permitted under Section 7.2 of the Credit Agreement.
		

		
			Pledged Equity means the equity interests listed on Schedule 1, together with any other equity interests, certificates, options or rights of any nature whatsoever in respect of the equity interests of any Person that may be issued or granted to, or held by, any Grantor while this Agreement is in effect; provided that in no event shall more than 65% of the total outstanding equity interests of any Foreign Subsidiary or Excluded Foreign Holding Company constitute Pledged Equity.
		

		
			Pledged Notes means all promissory notes listed on Schedule 1, all Intercompany Notes at any time issued to any Grantor and all other promissory notes issued to or held by any Grantor (other than any individual promissory note which is less than $1,000,000 in principal amount, up to an aggregate of $3,500,000 for all such promissory notes excluded thereby at any time).
		

		
			Proceeds means all “proceeds” as such term is defined in Section 9-102 of the UCC and, in any event, shall include all dividends or other income from the Investment Property, collections thereon or distributions or payments with respect thereto.
		

		
			Receivable means any right to payment for goods sold or leased or for services rendered, whether or not such right is evidenced by an Instrument or Chattel Paper and whether or not it has been earned by performance (including any Accounts); it being acknowledged and agreed by Lender that any receivable paid into a Trust Account maintained by any Grantor for the benefit of an agency of the United States of America shall not be deemed to be a receivable within the meaning of this Agreement.
		

		
			Secured Obligations means, collectively,  Borrower Obligations and Guarantor Obligations.
		

		
			Securities Act means the Securities Act of 1933, as amended.
		

		
			Trademarks means (a) all trademarks, trade names, corporate names, company names, business names, fictitious business names, service marks, logos, designs and other source or business identifiers, and all goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith, whether in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision o international or regional body thereof, or otherwise, and all common-law rights related thereto, and (b) the right to obtain all renewals thereof.
		

		
			
		

		
			

		 

		

			-5-

		

		

			 

		

		

		
			 
		

		
			Trademark Licenses means, collectively, each written agreement providing for the grant by or to any Grantor of any right to use any Trademark.
		

		
			UCC means the Uniform Commercial Code as in effect on the date hereof and from time to time in the State of New York, provided that if by reason of mandatory provisions of law, the perfection or the effect of perfection or non-perfection of the security interests in any Collateral or the availability of any remedy hereunder is governed by the Uniform Commercial Code as in effect on or after the date hereof in any other jurisdiction, “UCC” means the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions hereof relating to such perfection or effect of perfection or non-perfection or availability of such remedy.
		

		
			2.Guarantee.
		

		
			2.1Guarantee.
		

		
			(a)Each of the Guarantors hereby, jointly and severally, unconditionally and irrevocably, guarantees to Lender and its successors, indorsees, transferees and permitted assigns, the prompt and complete payment and performance by Borrower when due (whether at the stated maturity, by acceleration or otherwise) of Borrower Obligations.
		

		
			(b)Anything herein or in any other Loan Document to the contrary notwithstanding, the maximum liability of each Guarantor hereunder and under the other Loan Documents shall in no event exceed the amount which can be guaranteed by such Guarantor under applicable federal and state laws relating to the insolvency of debtors or any applicable laws relating to fraudulent conveyances or fraudulent transfers (after giving effect to the right of contribution established in Section 2.2).  The provisions of this Section 2.1(b) shall be implemented automatically without the need for any amendment or modification to the Loan Documents.
		

		
			(c)Each Guarantor agrees that the Secured Obligations may at any time and from time to time exceed the amount of the liability of such Guarantor hereunder without impairing the guarantee contained in this Section 2 or affecting the rights and remedies of the Lender hereunder.
		

		
			(d)The guarantee contained in this Section 2 shall remain in full force and effect until all of the Secured Obligations shall have been Paid in Full.
		

		
			(e)No payment made by Borrower, any of the Guarantors, any other guarantor or any other Person or received or collected by Lender from Borrower, any of the Guarantors, any other guarantor or any other Person by virtue of any action or proceeding or any set-off or appropriation or application at any time or from time to time in reduction of or in payment of the Secured Obligations shall be deemed to modify, reduce, release or otherwise affect the liability of any Guarantor hereunder which shall, notwithstanding any such payment (other than any payment made by such Guarantor in respect of the Secured Obligations or any payment received or collected from such Guarantor in respect of the Secured Obligations), remain liable for the Secured Obligations up to the maximum liability of such Guarantor hereunder until the Secured Obligations are Paid in Full.
		

		
			
		

		
			

		 

		

			-6-

		

		

			 

		

		

		
			 
		

		
			2.2Right of Contribution.  Each Guarantor hereby agrees that to the extent that a Guarantor shall have paid more than its proportionate share of any payment made hereunder, such Guarantor shall be entitled to seek and receive contribution from and against any other Guarantor hereunder which has not paid its proportionate share of such payment.  Each Guarantor’s right of contribution shall be subject to the terms and conditions of Section 2.3.  The provisions of this Section 2.2 shall in no respect limit the obligations and liabilities of any Guarantor to Lender, and each Guarantor shall remain liable to Lender for the full amount guaranteed by such Guarantor hereunder.
		

		
			2.3No Subrogation.  Notwithstanding any payment made by any Guarantor hereunder or any set-off or application of funds of any Guarantor by Lender, no Guarantor shall be entitled to be subrogated to any of the rights of Lender against Borrower or any other Guarantor or any collateral security or guarantee or right of offset held by Lender for the payment of the Secured Obligations, nor shall any Guarantor seek or be entitled to seek any contribution or reimbursement from Borrower or any other Guarantor in respect of payments made by such Guarantor hereunder, until all of the Secured Obligations are Paid in Full;  provided that any such right of contribution or reimbursement against any Borrower or any other Guarantor (including any right under Section 2.2) shall be irrevocably and automatically waived in the event the Pledged Equity or other equity securities of such Borrower or other Guarantor are sold or otherwise transferred or disposed of in connection with the exercise of rights and remedies by Agent (including in connection with a consensual sale, transfer or other disposition in lieu of foreclosure) and in connection with such sale or transfer, all or a portion of the Secured Obligations are Paid in Full.  If any amount shall be paid to any Guarantor on account of such subrogation rights at any time when all of the Secured Obligations shall not have been Paid in Full, such amount shall be held by such Guarantor in trust for Lender, segregated from other funds of such Guarantor, and shall, forthwith upon receipt by such Guarantor, be turned over to Lender in the form received by such Guarantor (duly indorsed by such Guarantor to Lender, if required), to be applied against the Secured Obligations in accordance with Lender’s sole discretion.
		

		
			2.4Amendments, etc. with respect to the Secured Obligations.  Each Guarantor shall remain obligated hereunder notwithstanding that, without any reservation of rights against any Guarantor and without notice to or further assent by any Guarantor, any demand for payment of any of the Secured Obligations made by Lender may be rescinded by Lender and any of the Secured Obligations continued, and the Secured Obligations, or the liability of any other Person upon or for any part thereof, or any collateral security or guarantee therefor or right of offset with respect thereto, may, from time to time, in whole or in part, be renewed, extended, amended, modified, accelerated, compromised, waived, surrendered or released by Lender, and the Credit Agreement and the other Loan Documents and any other documents executed and delivered in connection therewith may be amended, modified, supplemented or terminated, in whole or in part, as Lender may deem advisable from time to time, and any collateral security, guarantee or right of offset at any time held by Lender for the payment of the Secured Obligations may be sold, exchanged, waived, surrendered or released.  Lender shall not have any obligation to protect, secure, perfect or insure any Lien at any time held by it as security for the Secured Obligations or for the guarantee contained in this Section 2 or any property subject thereto. 
		

		
			2.5Guarantee Absolute and Unconditional.  Each Guarantor waives to the maximum extent permitted by applicable law any and all notice of the creation, renewal, extension or accrual
		

		
			
		

		
			

		 

		

			-7-

		

		

			 

		

		

		
			 
		

		
			of any of the Secured Obligations and notice of or proof of reliance by Lender upon the guarantee contained in this Section 2 or acceptance of the guarantee contained in this Section 2;  the Secured Obligations, and any of them, shall conclusively be deemed to have been created, contracted or incurred, or renewed, extended, amended or waived, in reliance upon the guarantee contained in this Section 2,  and all dealings between Borrower and any of the Guarantors, on the one hand, and Lender, on the other hand, likewise shall be conclusively presumed to have been had or consummated in reliance upon the guarantee contained in this Section 2.  Each Guarantor waives to the maximum extent permitted by applicable law (a) diligence, presentment, protest, demand for payment and notice of default or nonpayment to or upon Borrower or any of the Guarantors with respect to the Secured Obligations, (b) notice of the existence or creation or non-payment of all or any of the Secured Obligations, and (c) all diligence in collection or protection of or realization upon any Secured Obligations or any security for or guaranty of any Secured Obligations.  Each Guarantor understands and agrees that the guarantee contained in this Section 2 shall be construed as a continuing, absolute and unconditional guarantee of payment without regard to (i) the validity or enforceability of the Credit Agreement or any other Loan Document, any of the Secured Obligations or any other collateral security therefor or guarantee or right of offset with respect thereto at any time or from time to time held by Lender, (ii) any defense, set-off or counterclaim (other than a defense of payment or performance) whatsoever which may at any time be available to or be asserted by Borrower or any other Person against Lender, or (iii) any other circumstance whatsoever (with or without notice to or knowledge of Borrower or such Guarantor) which constitutes, or might be construed to constitute, an equitable or legal discharge of Borrower for the Secured Obligations (other than a defense of payment or performance), or of such Guarantor under the guarantee contained in this Section 2,  in bankruptcy or in any other instance.  When making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Guarantor, Lender may, but shall be under no obligation to, make a similar demand on or otherwise pursue such rights and remedies as it may have against Borrower, any other Guarantor or any other Person or against any collateral security or guarantee for the Secured Obligations or any right of offset with respect thereto, and any failure by Lender to make any such demand, to pursue such other rights or remedies or to collect any payments from Borrower, any other Guarantor or any other Person or to realize upon any such collateral security or guarantee or to exercise any such right of offset, or any release of Borrower, any other Guarantor or any other Person or any such collateral security, guarantee or right of offset, shall not relieve any Guarantor of any obligation or liability hereunder, and shall not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of Lender against any Guarantor.  For the purposes hereof “demand” shall include the commencement and continuance of any legal proceedings.  Each Guarantor waives any right that it may have under such applicable law to require that Agent commence action against Borrower or any other person or against any of the Collateral.
		

		
			Lender may, from time to time, at its sole discretion and without notice to any Guarantor (or any of them), take any or all of the following actions: (a) retain or obtain a security interest in any property to secure any of the Secured Obligations or any obligation hereunder, (b) retain or obtain the primary or secondary obligation of any obligor or obligors with respect to any of the Secured Obligations, (c) extend or renew any of the Secured Obligations for one or more periods (whether or not longer than the original period), alter or exchange any of the Secured Obligations, or release or compromise any obligation of any Guarantor or any obligation of any nature of any other obligor with respect to any of the Secured Obligations, (d) release any guaranty or right of
		

		
			
		

		
			

		 

		

			-8-

		

		

			 

		

		

		
			 
		

		
			offset or its security interest in, or surrender, release or permit any substitution or exchange for, all or any part of any property securing any of the Secured Obligations or any obligation hereunder, or extend or renew for one or more periods (whether or not longer than the original period) or release, compromise, alter or exchange any obligations of any nature of any obligor with respect to any such property, and (e) resort to any Guarantor for payment of any of the Secured Obligations when due, whether or not Lender shall have resorted to any property securing any of the Secured Obligations or any obligation hereunder or shall have proceeded against any other Guarantor or any other obligor primarily or secondarily obligated with respect to any of the Secured Obligations.
		

		
			2.6Payments.  Each Guarantor hereby guarantees that payments hereunder will be paid to Lender without set-off or counterclaim (other than for the defense of payment or performance in full) in Dollars at the office of Lender specified in the Credit Agreement.
		

		
			2.7Financial Condition.  Each Guarantor hereby assumes responsibility for being and remaining informed of the financial condition of Borrower and of all other circumstances bearing upon the risk of nonpayment of amounts owing under the Credit Agreement which diligent inquiry would reveal and agrees that Lender shall not have a duty to advise such Guarantor of information known to it regarding such condition or any such circumstances.
		

		
			3.Grant of Security Interest.
		

		
			Each Grantor hereby grants to Lender a security interest in all of its Collateral, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Secured Obligations.
		

		
			4.Representations and Warranties.
		

		
			To induce Lender to enter into the Credit Agreement and to induce Lender to make extensions of credit to Borrower thereunder, each Grantor jointly and severally hereby represents and warrants to Lender that:
		

		
			4.1Title.  Except for Permitted Liens, the Grantors own each item of the Collateral free and clear of any and all Liens.
		

		
			4.2Perfected First Priority Liens.  The security interests granted pursuant to this Agreement pursuant to Article 8 and Article 9 of the UCC (a) upon completion of the filings and other actions specified on Schedule 2 (which, in the case of all filings and other documents referred to on Schedule 2,  shall be delivered to Lender in completed and, if applicable, duly executed form on the Closing Date or on such later date as permitted by the terms of this Agreement or the Credit Agreement) will constitute valid perfected security interests as of such date (to the extent perfection can be accomplished by such filing or action) in all of the Collateral in favor of Lender as collateral security for each Grantor’s Obligations, enforceable in accordance with the terms hereof against all creditors of each Grantor (subject to the effects of bankruptcy, insolvency and similar laws affecting the enforceability of creditors’ rights generally and to general equitable principles) and any Persons purporting to purchase any Collateral from each Grantor, and (b) are prior to all other Liens on the Collateral in existence on the date hereof except for Permitted Liens.
		

		
			
		

		
			

		 

		

			-9-

		

		

			 

		

		

		
			 
		

		
			4.3Grantor Information.  On the date hereof, Schedule 3 sets forth (a) each Grantor’s jurisdiction of organization, (b) the location of each Grantor’s chief executive office, (c) each Grantor’s exact legal name as it appears on its organizational documents, (d) each Grantor’s federal employer identification number, and (e) each Grantor’s organizational identification number.
		

		
			4.4Collateral Locations.  On the date hereof, Schedule 4 sets forth (a) each place of business of each Grantor (including its chief executive office), (b) all locations where all Inventory and the Equipment owned by each Grantor is kept, except (i) Inventory and Equipment that is “in transit” or out for repair or restoration, or (ii) Inventory and Equipment in the possession of employees in the ordinary course of business, and (c) whether each such Collateral location and place of business (including each Grantor’s chief executive office) is owned or leased (and if leased, specifies the complete name and notice address of each lessor).  On the date hereof, no Collateral is located outside the United States or (except for Inventory and Equipment within the scope of clause (b) above) in the possession of any lessor, bailee, warehouseman or consignee, except as indicated on Schedule 4.
		

		
			4.5Certain Property.  None of the Collateral constitutes, or is the Proceeds of, (a) Farm Products, (b) Health-Care-Insurance Receivables or (c) vessels, aircraft or any other property subject to any certificate of title or other registration statute of the United States, any State or other jurisdiction, except for motor vehicles owned by the Grantors and used by employees of the Grantors in the ordinary course of business and subject to clause (a) of the definition of Excluded Property.
		

		
			4.6Investment Property.
		

		
			(a)The shares of Pledged Equity pledged by each Grantor hereunder constitute all the issued and outstanding equity interests of each Issuer owned by such Grantor or,  in the case of any Foreign Subsidiary or Excluded Foreign Holding Company, 65% of all issued and outstanding equity interests of such Foreign Subsidiary or Excluded Foreign Holding Company.  All certificates, if any evidencing the Pledged Equity pledged by any Grantor hereunder as of the date hereof have been delivered to Lender.
		

		
			(b)All of the Pledged Equity issued by any Subsidiary of any Grantor has been duly and validly issued and, if shares of corporate stock, is fully paid and nonassessable (to the extent applicable).  Each Grantor has the right and requisite authority to pledge, assign, transfer, deliver, deposit and set over the Pledged Equity owned by such Grantor to Lender as provided herein.  No consent,  approval, authorization or other order or other action by, and no notice to or filing with, any governmental entity or any other Person which has not yet been obtained or made is required either (i) for the pledge by any Grantor of the Pledged Equity pursuant to this Agreement or (ii) for the exercise by Lender of the voting or other rights in respect of the Pledged Equity provided for in this Agreement or the remedies in respect of the Pledged Equity pursuant to this Agreement, except as may be required in connection with such disposition by laws affecting the offering and sale of securities generally or the UCC.  The pledge by each Grantor of such Grantor’s Pledged Equity pursuant to this Agreement does not violate (i) the charter, by-laws, operating agreement or other organizational documents of any Grantor or any Issuer that is a Subsidiary of any Grantor, or any indenture, mortgage or agreement to which any Grantor or issuer
		

		
			
		

		
			

		 

		

			-10-

		

		

			 

		

		

		
			 
		

		
			is bound, or (ii) any restriction on such transfer or encumbrance of Pledged Equity with respect to any Issuer that is a Subsidiary of any Grantor, or (iii) any securities law or other applicable law, in each case to with respect to the foregoing clauses (i), (ii) and (iii), except where such violation could not reasonably be expected to result in a Material Adverse Effect. With respect to any Pledged Equity constituting certificated securities, the delivery of the certificate representing such Pledged Equity endorsed to Lender or in blank will perfect Lender’s security interest in such Pledged Equity and any proceeds thereof by “control” (within the meaning of the applicable UCC).
		

		
			(c)Schedule 1 lists all Investment Property owned by each Grantor as of the Closing Date.  Each Grantor is the record and beneficial owner of, and has good and marketable title to, the Investment Property pledged by it hereunder, free of any and all Liens or options in favor of any other Person, except the security interest created by this Agreement and, in the case of Investment Property which does not constitute Pledged Equity or Pledged Notes, for Permitted Liens.
		

		
			4.7Receivables.
		

		
			(a)No amount payable to such Grantor under or in connection with any Receivable is evidenced by any Instrument or Chattel Paper which has not been delivered to Lender unless delivery thereof is excused by the provisions of Section 5.1 hereof.
		

		
			(b)The amounts represented by such Grantor to Lender from time to time as owing to such Grantor in respect of the Receivables (to the extent such representations are required by any of the Loan Documents) will at all such times be accurate in all material respects.
		

		
			4.8Intellectual Property.
		

		
			(a)On the date hereof, Schedule 5 lists all patented or registered Intellectual Property (and all applications for Patents or registrations thereof), material Copyright Licenses, material Trademark Licenses and material Patent Licenses owned by each Grantor.
		

		
			(b)On the date hereof, all material Intellectual Property owned by such Grantor is valid, subsisting, in-force, unexpired and enforceable, has not been abandoned, expired or lapsed and, to such Grantor’s knowledge, all such material Intellectual Property and all physical manifestations, embodiments or uses thereof does not infringe, misappropriate or dilute the Intellectual Property rights of any other Person.
		

		
			(c)On the date hereof, except as set forth in Schedule 5, none of the Intellectual Property owned by any Grantor is the subject of any licensing or franchise agreement pursuant to which such Grantor is the licensor or franchisor.
		

		
			(d)To the knowledge of Grantors, no holding, decision or judgment has been rendered by any governmental or administrative authority which would limit, invalidate, render unenforceable, cancel or question the validity or enforceability of, or any Grantor’s rights in, any Intellectual Property owned by any Grantor in any material respect (other than office actions issued in the ordinary course of prosecution of any pending applications for Patents or applications for registration of other Intellectual Property).
		

		
			
		

		
			

		 

		

			-11-

		

		

			 

		

		

		
			 
		

		
			(e)No action or proceeding is pending, or, to the knowledge of such Grantor, threatened in writing, on the date hereof (i) seeking to limit, invalidate, render unenforceable, cancel or question the validity or enforceability of any material Intellectual Property owned by such Grantor or any Grantor’s ownership interest therein, or (ii) which, if adversely determined, could reasonably be expected to have a Material Adverse Effect.
		

		
			(f)Each Grantor owns and possesses or has a license or other right to use all Intellectual Property as is necessary for the conduct of the businesses of such Grantor, without any infringement upon, misappropriation of or dilution of rights of others which could reasonably be expected to have a Material Adverse Effect.
		

		
			4.9Deposit and Other Accounts.  All Deposit Accounts and all other accounts maintained by each Grantor as of the date hereof (other than Exempt Accounts) are described on Schedule 6 hereto, which description includes for each such account the name of the Grantor maintaining such account, the name, address, telephone and fax numbers of the financial institution at which such account is maintained, the account number and the account officer, if any, of such account.
		

		
			4.10Credit Agreement.  Each Grantor makes each of the representations and warranties made by Borrower in Sections  5.1, 5.2, 5.3, 5.10 and 5.12  of the Credit Agreement to the extent applicable to such Grantor (which representations and warranties shall be deemed to have been renewed upon each borrowing under the Credit Agreement, except to the extent such representations and warranties relate to a specific earlier date, in which case such representations and warranties shall be true and correct in all material respects (without duplication of any materiality qualifiers) as of such earlier date).  Such representations and warranties are incorporated herein by this reference as if fully set forth herein.
		

		
			5.Covenants.
		

		
			Each Grantor covenants and agrees with Lender that, from and after the date of this Agreement until the Secured Obligations shall have been Paid in Full:
		

		
			5.1Delivery of Instruments, Certificated Securities and Chattel Paper.  If any amount payable under or in connection with any of the Collateral with a value in excess of $1,000,000 individually or $3,500,000 in the aggregate for all Grantors at any time shall be or become evidenced by any Instrument, Certificated Security or Chattel Paper, other than checks for deposit, such Instrument, Certificated Security or Chattel Paper shall be promptly (within five (5) Business Days) following receipt thereof delivered to Lender, duly indorsed in a manner reasonably satisfactory to Lender, to be held as Collateral pursuant to this Agreement and in the case of such Chattel Paper constituting Electronic Chattel Paper, the applicable Grantor shall cause Lender to have control thereof within the meaning set forth in Section 9-105 of the UCC.  In the event that an Event of Default shall have occurred and be continuing, upon the request of Lender, any Instrument, Certificated Security or Chattel Paper not theretofore delivered to Lender and at such time being held by any Grantor shall be promptly (within five (5) Business Days of a written request) delivered to Lender, duly indorsed in a manner reasonably satisfactory to Lender, to be held as Collateral pursuant to this Agreement and in the case of Electronic Chattel Paper, the
		

		
			
		

		
			

		 

		

			-12-

		

		

			 

		

		

		
			 
		

		
			applicable Grantor shall cause Lender to have control thereof within the meaning set forth in Section 9-105 of the UCC.
		

		
			5.2Maintenance of Perfected Security Interest: Further Documentation.
		

		
			(a)Such Grantor shall maintain the security interest created by this Agreement as a perfected security interest in the Collateral having the priority described in Section 4.2 and shall defend such security interest against the claims and demands (other than with respect to matters of priority with respect to Permitted Liens where such Permitted Liens are not prohibited from having priority over the security interests granted herein) of all Persons whomsoever.
		

		
			(b)At any time and from time to time, promptly following the written request of Lender, and at the sole expense of such Grantor, such Grantor will promptly and duly execute and deliver, and have recorded, such further instruments and documents and take such further actions as Lender may reasonably request for the purpose of obtaining or preserving the full benefits of this Agreement and of the rights, and powers herein granted, including (i) filing any financing or continuation statements under the UCC (or other similar laws) in effect in any jurisdiction with respect to the security interests created hereby, and (ii) in the case of Investment Property, Deposit Accounts (other than Exempt Accounts), Electronic Chattel Paper with a face amount in excess of $1,000,000 individually and $3,500,000 in the aggregate for all Grantors and Letter of Credit Rights with respect to Letters of Credit with a face amount in excess of $1,000,000 individually and $3,500,000 in the aggregate for all Grantors and any other relevant Collateral, taking any actions necessary to enable Lender to obtain “control” (within the meaning of the applicable UCC) with respect thereto, in each case pursuant to documents in form and substance reasonably satisfactory to Lender.
		

		
			(d)Each Grantor authorizes Lender to, at any time and from time to time, file financing statements, continuation statements, and amendments thereto that describe the Collateral (including describing the Collateral as “all assets” of each Grantor, or words of similar effect), and which contain any other information required pursuant to the UCC for the sufficiency of filing office acceptance of any financing statement, continuation statement, or amendment, and each Grantor agrees to furnish any such information to Lender promptly upon Lender’s reasonable request.  Any such financing statement, continuation statement, or amendment may be signed (to the extent signature of a Grantor is required under applicable law) by Lender on behalf of any Grantor and may be filed at any time in any jurisdiction.
		

		
			(e)Each Grantor shall, at any time and from time to time, take such steps as Lender may reasonably request for Lender (i) use commercially reasonable efforts to obtain an acknowledgement, in form and substance reasonably satisfactory to Lender, of any bailee having possession of any of the Collateral with a value exceeding $1,000,000 individually or $3,500,000 in the aggregate for all such bailees, stating that the bailee holds such Collateral for Lender, (ii) to obtain “control” of any letter-of-credit rights, or electronic chattel paper (as such terms are defined by the UCC with corresponding provisions thereof defining what constitutes “control” for such items of Collateral) in each case with a value in excess of $1,000,000 individually or $3,500,000 in the aggregate, with any agreements establishing control to be in form and substance reasonably satisfactory to Lender, and (iii) otherwise to insure the continued perfection and priority of
		

		
			
		

		
			

		 

		

			-13-

		

		

			 

		

		

		
			 
		

		
			Lender’s security interest in any of the Collateral and of the preservation of its rights therein as granted or purported to be granted hereunder or under any of the other Loan Documents.
		

		
			5.3Changes in Locations,  Name, etc.  Such Grantor shall not, except upon ten (10) Business Days’ prior written notice (or such lesser notice to which Lender may agree in writing in its sole discretion) to Lender and delivery to Lender of all additional financing statements and other documents reasonably requested by Lender as to the validity, perfection and priority of the security interests provided for herein:
		

		
			(i)change the location of its chief executive office from that specified on Schedule 3 or in any subsequent notice delivered pursuant to this Section 5.3; or
		

		
			(ii)change its name, identity or corporate or limited liability company structure or jurisdiction of organization.
		

		
			(b)Notices.  Such Grantor will advise Lender promptly upon obtaining knowledge thereof, in reasonable detail, of any Lien (other than Permitted Liens) on any of the Collateral which would adversely affect the ability of Lender to exercise any of its remedies hereunder.
		

		
			5.4Investment Property.
		

		
			(a)All certificates and/or instruments evidencing the Pledged Equity on the date hereof shall be delivered to and held or on behalf of the Lender pursuant hereto.  All Pledged Equity shall be accompanied by (a) duly executed instruments of transfer to be assigned in blank (“Instrument of Transfer”), substantially in the form of Annex II attached hereto or otherwise in form and substance satisfactory to Lender, (b) a duly executed irrevocable proxy, in substantially the form of Annex III hereto (“Irrevocable Proxy”), and (c) to the extent the Issuer thereof is a Subsidiary of any Grantor, a duly acknowledged equity interest registration page, in blank, from the applicable Issuer, substantially in the form of Annex IV hereto or otherwise in form and substance reasonably satisfactory to Lender.  If such Grantor shall hereafter become entitled to receive or shall receive any certificate, option or rights in respect of the equity interests of any Issuer constituting Collateral, whether in addition to, in substitution of, as a conversion of, or in exchange for, any of the Pledged Equity, or otherwise in respect thereof, such Grantor shall accept the same as the agent of Lender, hold the same in trust for Lender and deliver the same promptly to Lender in the form received, duly indorsed by such Grantor to Lender, if required, together with an undated Instrument of Transfer covering such certificate duly executed in blank by such Grantor and with, if Lender so requests, signature guaranteed, to be held by Lender, subject to the terms hereof, as additional Collateral for the Secured Obligations.  If any Grantor acquires Pledged Equity with respect to any Issuer following the date hereof that is not an Issuer of Pledged Equity as of the date hereof, such Grantor shall deliver an executed Irrevocable Proxy and (to the extent the Issuer thereof is a Subsidiary of any Grantor) a Registration Page with respect to such new Issuer to Lender.  Upon the occurrence and during the continuance of an Event of Default, (i) any sums paid upon or in respect of the Investment Property upon the liquidation or dissolution of any Issuer shall be paid over to Lender to be held, at Lender’s option, either by it hereunder as additional Collateral for the Secured Obligations or applied to the Secured Obligations as provided in Section 6.5,  and (ii) in case any distribution of capital shall be made on or in respect of the
		

		
			
		

		
			

		 

		

			-14-

		

		

			 

		

		

		
			 
		

		
			Investment Property or any property which constitutes Collateral shall be distributed upon or with respect to the Investment Property pursuant to the recapitalization or reclassification of the capital of any Issuer or pursuant to the reorganization thereof, the property so distributed shall, unless otherwise subject to a perfected Lien in favor of Lender, be delivered to Lender to be held, at Lender’s option, either by it hereunder as additional Collateral for the Secured Obligations or applied to the Secured Obligations as provided in Section 6.5.  Upon the occurrence and during the continuance of an Event of Default, if any sums of money or property so paid or distributed in respect of the Investment Property shall be received by such Grantor, such Grantor shall, until such money or property is paid or delivered to Lender, hold such money or property in trust for Lender, segregated from other funds of such Grantor, as additional Collateral for the Secured Obligations.
		

		
			(b)Without the prior written consent of Lender (which consent shall not be unreasonably withheld, delayed or conditioned with respect to clause (i) below), such Grantor will not (i) vote to enable, or take any other action to permit, any Issuer to issue any equity interests of any nature or to issue any other securities or interests convertible into or granting the right to purchase or exchange for any equity interests of any nature of any Issuer (except pursuant to a transaction permitted by the Credit Agreement where such equity interests are issued to such Grantor and pledged pursuant to this Agreement) or to alter the voting rights with respect to any equity interests of any Issuer in any nature (ii) sell, assign, transfer, exchange, or otherwise dispose of, or grant any option with respect to, the Investment Property or Proceeds thereof (except pursuant to a transaction expressly permitted by the Credit Agreement) other than, with respect to Investment Property not constituting Pledged Equity or Pledged Notes, any such action which is not prohibited by the Credit Agreement, (iii) create, incur or permit to exist any Lien or option in favor of, or any claim of any Person with respect to, any of the Investment Property or Proceeds thereof, or any interest therein, except for Permitted Liens, or (iv) enter into any agreement or undertaking restricting the right or ability of such Grantor or Agent to sell, assign or transfer any of the Investment Property or Proceeds thereof, except, with respect to such Investment Property, shareholders’ agreements entered into by such Grantor with respect to Persons in which such Grantor maintains an ownership interest of 50% or less.
		

		
			(c)In the case of each Grantor (other than Parent) which is an Issuer, such Issuer agrees that (i) it will be bound by the terms of this Agreement relating to the Investment Property issued by it and will comply with such terms insofar as such terms are applicable to it, (ii) it will notify Lender promptly in writing of the occurrence of any of the events described in Section 5.4(a) with respect to the Investment Property issued by it and (iii) the terms of Sections 6.3(c) and 6.7 and each Irrevocable Proxy with respect to the Pledged Equity of such Grantor shall apply to such Grantor with respect to all actions that may be required of it pursuant to Section 6.3(c) or 6.7 or such Irrevocable Proxy regarding the Investment Property issued by it.
		

		
			5.5Intellectual Property.
		

		
			(a)Such Grantor (either itself or through licensees) will (i) continue to use each material Trademark owned by such Grantor and make appropriate filings evidencing such use to the extent required by applicable law to maintain such material Trademark in full force with respect to each class of goods for which such material Trademark is currently used, free from any claim of abandonment for non-use, (ii) use such material Trademark with the appropriate notice of registration and all other notices and legends required by applicable law to avoid any loss of rights,
		

		
			
		

		
			

		 

		

			-15-

		

		

			 

		

		

		
			 
		

		
			in each country or jurisdiction in which Grantor has rights in such material Trademark as of the date hereof (iii) not adopt or use any other Trademark which is confusingly similar or a colorable imitation of such material Trademark unless such Grantor shall grant to Lender a perfected security interest in such mark pursuant to this Agreement, and (iv) not (and not knowingly permit any licensee or sublicensee thereof to) knowingly do any act or knowingly omit to do any act whereby such material Trademark may become invalidated, forfeited, lapsed, abandoned, expired or impaired in any way.
		

		
			(b)Such Grantor (either itself or through licensees) will not knowingly do any act, or knowingly omit to do any act, whereby any material Patent owned by such Grantor may become invalidated, forfeited, lapsed, abandoned, expired or dedicated to the public or otherwise impaired.
		

		
			(c)Such Grantor (either itself or through licensees) will not (and will not knowingly permit any licensee or sublicensee thereof to) knowingly do any act or knowingly omit to do any act whereby any  material Copyright owned by such Grantor may become invalidated, forfeited, lapsed, abandoned, expired or dedicated to the public domain or otherwise impaired.
		

		
			(d)Such Grantor (either itself or through licensees) will not do any act that knowingly uses any Intellectual Property to infringe, misappropriate or dilute the intellectual property rights of any other Person.
		

		
			(e)Such Grantor will notify Lender immediately (but in any event within thirty (30) days) if it knows that any application or registration or issued patent for any material Intellectual Property owned by such Grantor may become invalidated, forfeited, lapsed, abandoned, expired, impaired in any way or dedicated to the public (other than through expiration of their full statutory term), or of any materially adverse determination in any proceeding against such Grantor (including the institution of, or any such determination in any proceeding in the United States Patent and Trademark Office, the United States Copyright Office or any court or tribunal in any country or jurisdiction) regarding, such Grantor’s ownership of, or the validity or enforceability of, any material Intellectual Property owned by such Grantor or such Grantor’s right to register the same or to own and maintain the same (other than office actions issued in the ordinary course of prosecution of any pending applications for Patents or applications for registration of other Intellectual Property).
		

		
			(f)Whenever such Grantor, either by itself or through any agent, employee, licensee or designee, files an application for the registration of any Intellectual Property with the United States Patent and Trademark Office, the United States Copyright Office or any similar office or agency in any other country or any political subdivision thereof or any regional or international body, such Grantor shall report such filing to Lender concurrently with the next delivery of financial statements of Borrower pursuant to Section 6.1.1 or 6.1.2 of the Credit Agreement, as applicable.  Upon the request of Lender, such Grantor shall execute and deliver, and have recorded, any and all agreements, instruments, documents, and papers as Lender may reasonably request to evidence Lender’s security interest in any Copyright, Patent or Trademark or other Intellectual Property owned by such Grantor and the goodwill and general intangibles of such Grantor relating thereto or represented thereby.
		

		
			
		

		
			

		 

		

			-16-

		

		

			 

		

		

		
			 
		

		
			(g)Such Grantor will take all reasonable and necessary, as determined in its reasonably business judgment, steps to maintain and pursue each application (and to obtain the relevant registration or issued patent) and to maintain the validity, in-force status and enforceability of each registration and issued patent of all material Intellectual Property owned by it.
		

		
			(h)In the event that any Intellectual Property owned by such Grantor is, to the knowledge of such Grantor, infringed upon or misappropriated or diluted by a third party, such Grantor shall (i) take such actions as such Grantor shall reasonably deem appropriate under the circumstances to protect such Intellectual Property and (ii) if such Intellectual Property is of material economic value, promptly (and in any event within ten (10) Business Days) notify Lender after it learns thereof and, to the extent, in its reasonable judgment, such Grantor determines it appropriate under the circumstances, sue for infringement, misappropriation or dilution, to seek injunctive relief where appropriate and to recover any and all damages for such infringement, misappropriation or dilution.
		

		
			5.6Reserved.
		

		
			5.7Other Matters.   If requested by Lender, each of the Grantors shall use commercially reasonable efforts to cause to be delivered to Lender a Collateral Access Agreement with respect to Borrower’s chief executive office in a form reasonably satisfactory to Lender, and each of the Grantors shall, at the written request of Lender, use commercially reasonable efforts to cause to be delivered to Lender a Collateral Access Agreement with respect to other leased real property or other locations (including bailee and third party warehouse locations) where (a) books and records are not duplicated at the chief executive office or (b) Collateral having a fair market value in excess of $1,000,000 individually and $3,500,000 in the aggregate for such locations are located. Such requirement may be waived at the option of Lender.
		

		
			5.8Commercial Tort Claims. If any Grantor shall at any time acquire any Commercial Tort Claim in excess of $1,000,000, such Grantor shall promptly (following knowledge of the existence thereof) notify Lender thereof in writing, therein providing a reasonable description and summary thereof, and upon delivery thereof to Lender, such Grantor shall be deemed to thereby grant to Lender (and such Grantor hereby grants to Lender) a security interest in such Commercial Tort Claim and all proceeds thereof.
		

		
			5.9Credit Agreement. Each of the Grantors covenants that it will, and, if necessary, will cause or enable Borrower to, fully comply with each of the covenants and other agreements set forth in the Credit Agreement applicable to such Grantor or Borrower, as applicable.
		

		
			6.Remedial Provisions.
		

		
			6.1Reserved.
		

		
			6.2Communications with Obligors: Grantors Remain Liable.
		

		
			(a)For the purpose of enabling Lender to exercise rights and remedies under this Agreement after the occurrence and during the continuation of an Event of Default, each Grantor hereby grants to Lender an irrevocable (except upon Payment in Full of the Secured
		

		
			
		

		
			

		 

		

			-17-

		

		

			 

		

		

		
			 
		

		
			Obligations and termination of this Agreement), nonexclusive, worldwide, sublicensable, assignable, perpetual license (exercisable without payment of royalty or other compensation to such Grantor) to make, use, sell, offer for sale, import, export, reproduce, make derivatives works based upon, license or sublicense, and otherwise commercially exploit any Intellectual Property now owned or hereafter acquired by such Grantor during the continuation of any Event of Default, and wherever the same may be located, and including in such license access to all media in which any of the licensed items may be recorded or stored and to all computer software, accounts and programs used for the compilation or printout thereof.
		

		
			6.3Investment Property.
		

		
			(a)Unless an Event of Default shall have occurred and be continuing and Lender shall have given notice to the relevant Grantor of Lender’s intent to exercise its corresponding rights pursuant to Section 6.3(b), each Grantor shall be permitted to receive all cash dividends and distributions paid in respect of the Pledged Equity and all payments made in respect of the Pledged Notes, to the extent permitted in the Credit Agreement, and to exercise all voting and other rights with respect to the Investment Property; provided, that no vote shall be cast or other right exercised or action taken which could impair the Collateral or which would be inconsistent with or result in any violation of any provision of the Credit Agreement, this Agreement or any other Loan Document.
		

		
			(b)If an Event of Default shall occur and be continuing and Lender shall give concurrent notice of its election to exercise such rights to the relevant Grantor or Grantors, Lender shall have the right to (i) receive any and all cash dividends and distributions, payments or other Proceeds paid in respect of the Investment Property and make application thereof to the Secured Obligations in accordance with Section 6.5,  (ii) transfer and register any or all of the Investment Property in the name of Lender or its nominee, it being acknowledged by each Grantor (in its capacity as Grantor and, if such Grantor is an Issuer of any Investment Property, as Issuer) that such transfer and registration may be effected by Lender by the delivery of a Registration Page to the applicable Issuer reflecting Lender or its designee as the holder of such Investment Property, or otherwise by Lender  through its irrevocable appointment as attorney-in-fact pursuant to this Agreement and each Irrevocable Proxy, (iii) exercise, or permit its nominee to exercise, all voting and other rights pertaining to such Investment Property as a holder of such Investment Property, with full power of substitution to do so, and (iv) exercise, or permit its nominee to exercise, any and all rights of conversion, exchange and subscription and any other rights, privileges or options pertaining to such Investment Property as if it were the absolute owner thereof (including the right to exchange at its discretion any and all of the Investment Property upon the merger, consolidation, reorganization, recapitalization or other fundamental change in the corporate or other structure of any Issuer, or upon the exercise by any Grantor or Lender of any right, privilege or option pertaining to such Investment Property, and in connection therewith, the right to deposit and deliver any and all of the Investment Property with any committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions as Lender may determine), and including with respect to the Pledged Equity, giving or withholding written consents of stockholders, partners or members, calling special meetings of stockholders, partners or members and voting at such meetings) and otherwise act with respect to the Investment Property as if Lender were the outright owner thereof, (v) exercise any other rights or remedies Lender may have under the UCC or other applicable law, and (vi) take any action and execute any instrument which Lender
		

		
			
		

		
			

		 

		

			-18-

		

		

			 

		

		

		
			 
		

		
			may deem necessary or advisable to accomplish the purposes of this Agreement, all without liability except to account for property actually received by it, but Lender shall have no duty to any Grantor to exercise any such right, privilege or option and shall not be responsible for any failure to do so or delay in so doing.
		

		
			(c)Each Grantor hereby authorizes and instructs each Issuer of any Investment Property pledged by such Grantor hereunder to (i) comply with any instruction received by it from Lender in writing that (x) states that an Event of Default has occurred and is continuing and (y) is otherwise in accordance with the terms of this Agreement (including Section 6.3(b)), without any other or further instructions from such Grantor, and each Grantor agrees that each Issuer shall be fully protected in so complying, and (ii) so long as an Event of Default exists, unless otherwise expressly permitted hereby, pay any dividends, distributions or other payments with respect to the Investment Property directly to Lender. 
		

		
			(d)Any transfer to Lender or its nominee, or registration in the name of Lender or its nominee, of the whole or any part of the Investment Property, whether by the delivery of a Registration Page to an Issuer or otherwise, shall be made solely for purposes of effectuating voting or other consensual rights with respect to the Investment Property in accordance with the terms of this Agreement and is not intended to effectuate any transfer of ownership of the Investment Property. Notwithstanding any delivery or modification of a Registration Page or exercise of an Irrevocable Proxy, Lender shall not be deemed the owner of, or assume any obligations of the owner or holder of any Investment Property unless and until Lender accepts such obligations in writing or otherwise takes steps to foreclose its security interest in the Investment Property and become the owner thereof under applicable law (including via sale as described in this Agreement).
		

		
			(e)Each Grantor further agrees that a breach of any of the covenants contained in this Section 6.3 will cause irreparable injury to Lender, that Lender shall have no adequate remedy at law in respect of such breach and, as a consequence, agrees that each and every covenant contained in this Section 6.3 shall be specifically enforceable against such Grantor, and each Grantor hereby waives and agrees not to assert any defenses against an action for specific performance of such covenants except for a defense that the Secured Obligations are not then due and payable in accordance with the agreements and instruments governing and evidencing such obligations.
		

		
			6.4Proceeds to be Turned Over To Agent. In addition to the rights of Lender specified in Section 6.1 with respect to payments of Receivables, if an Event of Default shall occur and be continuing, upon the request of Lender all Proceeds of Collateral received by any Grantor consisting of cash, checks and other cash equivalent items shall be held by such Grantor in trust for Lender, segregated from other funds of such Grantor, and shall, at the written request of Lender, forthwith (and, in any event, within two (2) Business Days) upon receipt by such Grantor, be turned over to Lender in the form received by such Grantor (duly indorsed by such Grantor to Lender, if required). All Proceeds received by Lender hereunder shall be applied to the Secured Obligations as provided in Section 6.5.
		

		
			6.5Application of Proceeds. At such intervals as may be agreed upon by Borrower and Lender, or, if an Event of Default shall have occurred and be continuing, at any time at Lender’s election, Lender may apply all or any part of Proceeds held in any collateral account established
		

		
			
		

		
			

		 

		

			-19-

		

		

			 

		

		

		
			 
		

		
			pursuant hereto or otherwise received by Lender to the payment of the Secured Obligations in accordance with Lender’s sole discretion.
		

		
			6.6Code and Other Remedies. If an Event of Default shall occur and be continuing, Lender, may exercise, in addition to all other rights and remedies granted to it in this Agreement and in any other instrument or agreement securing, evidencing or relating to the Secured Obligations, all rights and remedies of a secured party under the UCC or any other applicable law.  Without limiting the generality of the foregoing, Lender, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon any Grantor or any other Person (all and each of which demands, defenses, advertisements and notices are hereby waived to the extent permitted by law), may in such circumstances forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof, and/or may forthwith sell, lease, assign, give options to purchase, or otherwise dispose of and deliver the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s board or office of Lender or elsewhere upon such terms and conditions as it may deem advisable and at such prices as it may deem best, for cash or on credit or for future delivery with assumption of any credit risk. Lender may disclaim any warranties that might arise in connection with any such lease, assignment, grant of option or other disposition of Collateral and have no obligation to provide any warranties at such time. Lender shall have the right upon any such public sale or sales, and, to the extent permitted by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption in any Grantor, which right or equity is hereby waived and released. Such sales may be adjourned and continued from time to time with or without notice. Lender shall have the right to conduct such sales on any Grantor’s premises or elsewhere and shall have the right to use any Grantor’s premises without charge for such time or times as Lender deems necessary or advisable. Each Grantor further agrees, at Lender’s request and during the existence of an Event of Default, to assemble the Collateral and make it available to Lender at places which Lender shall reasonably select, whether at such Grantor’s premises or elsewhere. Lender shall apply the net proceeds of any action taken by it pursuant to this Section 6.6. after deducting all reasonable costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any of the Collateral or in any way relating to the Collateral or the rights of Lender hereunder, including attorneys’ fees and disbursements reimbursable pursuant to Section 9.4 of the Credit Agreement, to the payment of the Secured Obligations in accordance with Lender’s sole discretion. To the extent permitted by applicable law, each Grantor waives all claims, damages and demands it may acquire against Lender arising out of the exercise by it of any rights hereunder. If any notice of a proposed sale or other disposition of Collateral shall be required by law, such notice shall be deemed reasonable and proper if given at least ten (10) days before such sale or other disposition.
		

		
			6.7Registration Rights.  Each Grantor recognizes that Lender may be unable to effect a public sale of any or all the Pledged Equity, by reason of certain prohibitions contained in the Securities Act and applicable state securities laws or otherwise, and may be compelled to resort to one or more private sales thereof to a restricted group of purchasers which will be obliged to agree, among other things, to acquire such securities for their own account for investment and not with a view to the distribution or resale thereof.  Each Grantor acknowledges and agrees that any such private sale may result in prices and other terms less favorable than if such sale were a public sale. Lender shall be under no obligation to delay a sale of any of the Pledged Equity for the period of
		

		
			
		

		
			

		 

		

			-20-

		

		

			 

		

		

		
			 
		

		
			time necessary to permit the Issuer thereof to register such securities or other interests for public sale under the Securities Act, or under applicable state securities laws, even if such Issuer would agree to do so.
		

		
			6.8Waiver; Deficiency. Each Grantor waives, to the maximum extent permitted by applicable law, and agrees not to assert any rights or privileges which it may acquire under Section 9-626 of the UCC. Each Grantor shall remain liable for any deficiency if the proceeds of any sale or other disposition of the Collateral are insufficient for the Secured Obligations to be Paid in Full and the reasonable and documented fees and out-of-pocket disbursements of any attorneys employed by Lender to collect such deficiency (to the extent reimbursable under the Credit Agreement).
		

		
			7.Lender as Attorney-in Fact, etc. and its Duties.
		

		
			7.1Lender’s Appointment as Attorney-in-Fact, etc.
		

		
			(a)WHILE AN EVENT OF DEFAULT EXISTS, EACH GRANTOR HEREBY IRREVOCABLY CONSTITUTES AND APPOINTS LENDER AND ANY OFFICER OR AGENT THEREOF, WITH FULL POWER OF SUBSTITUTION, AS ITS TRUE AND LAWFUL ATTORNEY-IN-FACT AND PROXY WITH FULL IRREVOCABLE POWER AND AUTHORITY IN THE PLACE AND STEAD OF SUCH GRANTOR AND IN THE NAME OF SUCH GRANTOR OR IN ITS OWN NAME, FOR THE PURPOSE OF CARRYING OUT THE TERMS OF THIS AGREEMENT, TO TAKE ANY AND ALL APPROPRIATE ACTION AND TO EXECUTE ANY AND ALL DOCUMENTS AND INSTRUMENTS WHICH MAY BE NECESSARY OR DESIRABLE TO ACCOMPLISH THE PURPOSES OF THIS AGREEMENT OR TAKE ANY OTHER REMEDIAL ACTION WITH RESPECT TO COLLATERAL OTHERWISE DESCRIBED IN THIS AGREEMENT, THE CREDIT AGREEMENT OR THE OTHER LOAN DOCUMENTS, and, without limiting the generality of the foregoing, each Grantor hereby gives Lender the power and right, on behalf of and at the expense of such Grantor, without notice to or assent by such Grantor, to do any or all of the following:
		

		
			(i)in the name of such Grantor or its own name, or otherwise, take possession ofand indorse and collect any checks, drafts, notes, acceptances or other instruments for the payment of moneys due under any Receivable or with respect to any other Collateral and file any claim or take any other action or proceeding in any court of law or equity or otherwise deemed appropriate by Lender for the purpose of collecting any and all such moneys due under any Receivable or with respect to any other Collateral whenever payable;
		

		
			(ii)in the case of any Intellectual Property owned by such Grantor, execute and deliver, and have recorded, any and all agreements, instruments, documents and papers as Lender may request to evidence Lender’s security interest in such Intellectual Property and the goodwill and general intangibles of such Grantor relating thereto or represented thereby;
		

		
			
		

		
			

		 

		

			-21-

		

		

			 

		

		

		
			 
		

		
			(iii)discharge Liens levied or placed on or threatened against the Collateral, and effect any repairs or insurance called for by the terms of this Agreement and pay all or any part of the premiums therefor and the costs thereof;
		

		
			(iv)execute, in connection with any sale provided for in Section 6.6 or 6.7, any indorsements, assignments or other instruments of conveyance or transfer with respect to the Collateral;
		

		
			(v) (1) vote the Investment Property in any manner Lender deems advisable for or against all matters submitted or which may be submitted to a vote of shareholders, partners or members, as the case may be, (2) transfer and register in its name or in the name of its nominee the whole or any part of the Investment Property, (3) receive and collect any dividend or other payment or distribution in respect of or in exchange for the Investment Property and (4) take all such other actions with respect to Investment Properly authorized under Section 6.3 or 6.7 of this Agreement or otherwise authorized by this Agreement or the Other Loan Documents; and
		

		
			(vi) (1) direct any party liable for any payment under any of the Collateral to make payment of any and all moneys due or to become due thereunder directly to Lender or as Lender shall direct; (2) ask or demand for, collect, and receive payment of and receipt for, any and all moneys, claims and other amounts due or to become due at any time in respect of or arising out of any Collateral; (3) sign and indorse any invoices, freight or express bills, bills of lading, storage or warehouse receipts, drafts against debtors, assignments, verifications, notices and other documents in connection with any of the Collateral; (4) commence and prosecute any suits, actions or proceedings at law or in equity in any court of competent jurisdiction to collect the Collateral or any portion thereof and to enforce any other right in respect of any Collateral; (5) defend any suit, action or proceeding brought against such Grantor with respect to any Collateral; (6) settle, compromise or adjust any such suit, action or proceeding and, in connection therewith, give such discharges or releases as Lender may deem appropriate; (7) assign any Copyright, Patent or Trademark or other Intellectual Property, throughout the world for such term or terms, on such conditions, and in such manner, as Lender shall in its sole discretion determine; (8) vote any right or interest with respect to any Investment Property; (9) order good standing certificates and conduct lien searches in respect of such jurisdictions or offices as Lender may deem appropriate; and (10) generally sell, transfer, pledge and make any agreement with respect to or otherwise deal with any of the Collateral as fully and completely as though Lender were the absolute owner thereof for all purposes, and do, at Lender’s option and such Grantor’s expense, at any time, or from time to time, all acts and things which Lender deems necessary to protect, preserve or realize upon the Collateral and Lender’s security interests therein and to effect the intent of this Agreement, all as fully and effectively as such Grantor might do.
		

		
			THE POWER-OF-ATTORNEY AND PROXY GRANTED HEREBY IS COUPLED WITH AN INTEREST AND SHALL BE VALID AND IRREVOCABLE UNTIL (X) THE SECURED OBLIGATIONS HAVE BEEN INDEFEASIBLY PAID IN FULL IN ACCORDANCE WITH THE PROVISIONS OF THE CREDIT AGREEMENT, THE OTHER LOAN DOCUMENTS OR ANY OTHER GOVERNING DOCUMENTATION, AS
		

		
			
		

		
			

		 

		

			-22-

		

		

			 

		

		

		
			 
		

		
			APPLICABLE AND (Y) LENDER HAS NO FURTHER OBLIGATIONS UNDER THE CREDIT AGREEMENT, THE OTHER LOAN DOCUMENTS OR ANY OTHER DOCUMENTS (IT BEING UNDERSTOOD THAT ANY SUCH SECURED OBLIGATIONS WILL CONTINUE TO BE EFFECTIVE OR AUTOMATICALLY REINSTATED IF AT ANY TIME PAYMENT, IN WHOLE OR IN PART, OF ANY OF THE SECURED OBLIGATIONS IS RESCINDED OR MUST OTHERWISE BE RESTORED OR RETURNED BY LENDER FOR ANY REASON, INCLUDING AS A PREFERENCE, FRAUDULENT CONVEYANCE OR OTHERWISE UNDER ANY BANKRUPTCY, INSOLVENCY OR SIMILAR LAW, ALL AS THOUGH SUCH PAYMENT HAD NOT BEEN MADE; IT BEING FURTHER UNDERSTOOD THAT IN THE EVENT PAYMENT OF ALL OR ANY PART OF THE SECURED OBLIGATIONS IS RESCINDED OR MUST BE RESTORED OR RETURNED, ALL REASONABLE OUT-OF-POCKET COSTS AND EXPENSES (INCLUDING, WITHOUT LIMITATION, REASONABLE ATTORNEYS’ FEES AND DISBURSEMENTS) INCURRED BY LENDER IN DEFENDING AND ENFORCING SUCH REINSTATEMENT SHALL BE DEEMED TO BE INCLUDED AS A PART OF THE SECURED OBLIGATIONS) (THE OCCURRENCE OF THE FOREGOING, “TERMINATION”)). SUCH APPOINTMENT OF LENDER AS PROXY AND ATTORNEY-IN-FACT SHALL BE VALID AND IRREVOCABLE AS PROVIDED HEREIN NOTWITHSTANDING ANY LIMITATIONS TO THE CONTRARY SET FORTH IN THE CERTIFICATE OF INCORPORATION, CERTIFICATE OF FORMATION, ARTICLES OF ORGANIZATION, BY-LAWS, LIMITED LIABILITY COMPANY AGREEMENTS OR OTHER ORGANIZATIONAL DOCUMENTS OF ANY GRANTOR OR ISSUER OR CORPORATE OR LIMITED LIABILITY COMPANY LAW (OR SIMILAR LAW), AS APPLICABLE, OF THE STATE OF DELAWARE, OR ANY OTHER STATE OF ORGANIZATION OF ANY GRANTOR OR ISSUER. SUCH PROXY SHALL BE EFFECTIVE AUTOMATICALLY AND WITHOUT THE NECESSITY OF ANY ACTION (INCLUDING ANY TRANSFER OF ANY INVESTMENT PROPERTY ON THE RECORD BOOKS OF THE ISSUER THEREOF) BY ANY PERSON (INCLUDING THE ISSUER OF THE INVESTMENT PROPERTY OR ANY OFFICER OR AGENT THEREOF). IN ORDER TO FURTHER AFFECT THE TRANSFER OF RIGHTS WITH RESPECT TO PLEDGED EQUITY SET FORTH IN SECTION 6.3,  SECTION 6.7 OR ANY OTHER PROVISION OF THIS AGREEMENT IN FAVOR OF LENDER,  LENDER SHALL HAVE THE RIGHT, UPON THE OCCURRENCE AND DURING THE CONTINUANCE OF AN EVENT OF DEFAULT, TO PRESENT TO ANY ISSUER AN IRREVOCABLE PROXY AND/OR REGISTRATION PAGE.
		

		
			Upon exercise of the proxy set forth herein, all prior proxies given by any Grantor with respect to any of the Investment Property (other than to Lender or otherwise pursuant to the Loan Documents) are hereby revoked, and no subsequent proxies (other than to Lender or otherwise under the Loan Documents) will be given with respect to any of the Investment Property. Lender, as proxy, will be empowered and may exercise the irrevocable proxy to vote the Investment Property at any and all times, including but not limited to, at any meeting of shareholders, partners or members, as the case may be, however called, and at any adjournment thereof, or in any action by written consent, and may waive any notice otherwise required in connection therewith. To the fullest extent permitted by applicable law, Lender shall have no agency, fiduciary or other implied duties to any Grantor or any other party when acting in its capacity as such attorney-in-fact or proxy. Each Grantor hereby waives and releases any claims that it may otherwise have against Lender with respect to any breach or alleged breach of any such agency, fiduciary or other duty. Notwithstanding the foregoing grant of a power of attorney and proxy, Lender shall have no duty
		

		
			
		

		
			

		 

		

			-23-

		

		

			 

		

		

		
			 
		

		
			to exercise any such right or to preserve the same and shall not be liable for any failure to do so or for any delay in doing so.
		

		
			Anything in this Section 7.1(a) at to the contrary notwithstanding, Lender agrees that it will not exercise any rights under the power of attorney provided for in this Section 7.1(a) unless an Event of Default shall have occurred and be continuing.
		

		
			(b)If any Grantor fails to perform or comply with any of its agreements contained herein, Lender, at its option, but without any obligation so to do, may perform or comply, or otherwise cause performance or compliance, with such agreement.
		

		
			(c)Each Grantor hereby ratifies all that such attorneys shall lawfully do or cause to be done by virtue hereof. All powers, authorizations and agencies contained in this Agreement are coupled with an interest and are irrevocable until this Agreement is terminated and the security interests created hereby are released.
		

		
			7.2Duty of Lender.  Lender’s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in its possession shall be to deal with it in the same manner as Lender deals with similar property for its own account. Lender nor any of its officers, directors, employees or agents shall be liable for any failure to demand, collect or realize upon any of the Collateral or for any delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or any other Person or to take any other action whatsoever with regard to the Collateral or any part thereof. The powers conferred on Lender hereunder are solely to protect Lender’s interests in the Collateral and shall not impose any duty upon Lender to exercise any such powers. Lender shall be accountable only for amounts that it actually receives as a result of the exercise of such powers, and neither it nor any of its officers, directors, employees or agents shall be responsible to any Grantor for any act or failure to act hereunder.
		

		
			7.3Photocopy of this Agreement. A photographic or other reproduction of this Agreement shall be sufficient as a financing statement or other filing or recording document or instrument for filing or recording in any jurisdiction.
		

		
			8.Miscellaneous.
		

		
			8.1Amendments in Writing. None of the terms or provisions of this Agreement may be waived, amended, supplemented or otherwise modified except in accordance with Section 9.1 of the Credit Agreement.
		

		
			8.2Notices. All notices, requests and demands to or upon Agent or any Grantor hereunder shall be effected in the manner provided for in Section 9.2 of the Credit Agreement and each such notice, request or demand to or upon any Guarantor shall be addressed to such Guarantor in care of Borrower at Borrower’s notice address set forth on Schedule 1.
		

		
			8.3Indemnification by Grantors. Each Grantor hereby agrees, on a joint and several basis, to indemnify, exonerate and hold Lender and each of the officers, directors, employees, Affiliates and agents of Lender (each a “Lender Party”), except to the extent resulting from gross negligence or willful misconduct of such Lender Party as determined by a court of competent
		

		
			
		

		
			

		 

		

			-24-

		

		

			 

		

		

		
			 
		

		
			jurisdiction, free and harmless from and against any and all actions, causes of action, suits, losses, liabilities, damages and expenses, including Legal Costs (collectively, the “Indemnified Liabilities”), incurred by Lender Parties or any of them as a result of, or arising out of, or relating to (a) any tender offer, merger, purchase of equity interests, purchase of assets or other similar transaction financed or proposed to be financed in whole or in part, directly or indirectly, with the proceeds of any of the Loans, (b) the use, handling, release, emission, discharge, transportation, storage, treatment or disposal of any hazardous substance at any properly owned or leased by any Grantor or any Subsidiary, (c) any violation of any Environmental Laws with respect to conditions at any property owned or leased by any Grantor or any Subsidiary or the operations conducted thereon, (d) the investigation, cleanup or remediation of offsite locations at which any Grantor or any Subsidiary or their respective predecessors are alleged to have directly or indirectly disposed of hazardous substances, or (e) the execution, delivery, performance or enforcement of this Agreement or any other Loan Document by any Lender Party, except to the extent any such Indemnified Liabilities result from the applicable Lender Party’s or its officers, directors, employees, agents or Affiliates gross negligence, bad faith or willful misconduct as determined by a court of competent jurisdiction. If and to the extent that the foregoing undertaking may be unenforceable for any reason, each Grantor hereby agrees to make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. The agreements in this Section 8.3 shall survive repayment of the Secured Obligations (and termination of all commitments thereunder), any foreclosure under, or any modification, release or discharge of, any or all of the Collateral Documents and termination of this Agreement.
		

		
			8.4Enforcement Expenses.
		

		
			(a)Each Grantor agrees, on a joint and several basis, to pay or reimburse on demand Lender for all reasonable out-of-pocket costs and expenses (including Legal Costs) incurred in collecting against any Guarantor under the guarantee contained in Section 2 or otherwise enforcing or preserving any rights under this Agreement and the other Loan Documents in accordance with the terms of Section 9.4 of the Credit Agreement.
		

		
			(b)Each Grantor agrees to pay, and to hold Lender harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all stamp, excise, sales or other taxes which may be payable or determined to be payable with respect to any of the Collateral or in connection with any of the transactions contemplated by this Agreement.
		

		
			(c)The agreements in this Section 8.4 shall survive repayment of the Secured Obligations (and termination of all commitments thereunder), any foreclosure under, or any modification, release or discharge of, any or all of the Collateral Documents and termination of this Agreement.
		

		
			8.5Captions. Captions used in this Agreement are for convenience only and shall not affect the construction of this Agreement.
		

		
			8.6Nature of Remedies. All Secured Obligations of each Grantor and rights of Lender expressed herein or in any other Loan Document shall be in addition to and not in limitation of those provided by applicable law. No failure to exercise and no delay in exercising, on the part of
		

		
			
		

		
			

		 

		

			-25-

		

		

			 

		

		

		
			 
		

		
			Lender, any right, remedy, power or privilege hereunder, shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
		

		
			8.7Counterparts. This Agreement may be executed in any number of counterparts and by the different parties hereto on separate counterparts and each such counterpart shall be deemed to be an original, but all such counterparts shall together constitute but one and the same Agreement. Receipt by facsimile, emailed .pdf file or other similar form of electronic transmission of any executed signature page to this Agreement or any other Loan Document shall constitute effective delivery of such signature page.
		

		
			8.8Severability. The illegality or unenforceability of any provision of this Agreement or any instrument or agreement required hereunder shall not in any way affect or impair the legality or enforceability of the remaining provisions of this Agreement or any instrument or agreement required hereunder.
		

		
			8.9Entire Agreement. This Agreement, together with the other Loan Documents, embodies the entire agreement and understanding among the parties hereto and supersedes all prior or contemporaneous agreements and understandings of such Persons, verbal or written, relating to the subject matter hereof and thereof and any prior arrangements made with respect to the payment by any Grantor of (or any indemnification for) any fees, costs or expenses payable to or incurred (or to be incurred) by or on behalf of Lender.
		

		
			8.10Successors; Assigns. This Agreement shall be binding upon Grantors and Lender and their respective successors and permitted assigns, and shall inure to the benefit of Grantors and Lender and the successors and permitted assigns of Lender. No other Person shall be a direct or indirect legal beneficiary of, or have any direct or indirect cause of action or claim in connection with, this Agreement or any of the other Loan Documents. No Grantor may assign or transfer any of its rights or Obligations under this Agreement without the prior written consent of Lender.
		

		
			8.11Governing Law.  THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES.
		

		
			8.12Forum Selection; Consent to Jurisdiction.  ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH THIS AGREEMENT, SHALL BE BROUGHT AND MAINTAINED EXCLUSIVELY IN THE COURTS OF THE STATE OF NEW YORK SITTING IN NEW YORK COUNTY OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK; PROVIDED THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT LENDER’S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND.  EACH GRANTOR AND LENDER HEREBY EXPRESSLY AND IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK SITTING IN NEW YORK COUNTY AND THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK FOR THE PURPOSE OF ANY SUCH LITIGATION AS SET FORTH ABOVE.  EACH GRANTOR AND LENDER FURTHER IRREVOCABLY
		

		
			
		

		
			

		 

		

			-26-

		

		

			 

		

		

		
			 
		

		
			CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK.  EACH GRANTOR AND LENDER HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.
		

		
			8.13Waiver of Jury Trial.  EACH OF GRANTOR AND LENDER HEREBY WAIVES ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS UNDER THIS AGREEMENT AND ANY AMENDMENT, INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED OR WHICH MAY IN THE FUTURE BE DELIVERED IN CONNECTION HEREWITH AND AGREES THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.
		

		
			8.14Set-off. Each Grantor agrees that Lender has  all rights of set-off provided by applicable law, and in addition thereto, each Grantor agrees that at any time any Event of Default has occurred and is continuing, Lender may apply to the payment of any Secured Obligations, whether or not then due, any and all balances, credits, deposits, accounts or moneys of such Grantor then or thereafter with Lender (other than balances in Exempt Accounts that do not constitute Exempt Accounts pursuant to clause (a)(iv) of the definition thereof). Lender shall promptly provide subsequent notice of any such set-off to the applicable Grantor, provided that the failure to provide such notice shall not affect the validity of such set-off.
		

		
			8.15Acknowledgements. Each Grantor hereby acknowledges that:
		

		
			(a)it has been advised by counsel in the negotiation, execution and delivery of this Agreement and the other Loan Documents to which it is a party;
		

		
			(b)Lender has no fiduciary relationship with or duty to any Grantor arising out of or in connection with this Agreement or any of the other Loan Documents, and the relationship between the Grantors, on the one hand, and Lender, on the other hand, in connection herewith or therewith is solely that of debtor and creditor; and
		

		
			(c)no joint venture is created hereby or by the other Loan Documents or otherwise exists by virtue of the transactions contemplated hereby by Grantors and Lender.
		

		
			8.16Additional Grantors. Each Loan Party that is required to become a party to this Agreement pursuant to Section 6.7 of the Credit Agreement shall become a Grantor for all purposes of this Agreement upon execution and delivery by such Loan Party of a joinder agreement in a form reasonably satisfactory to Lender in its sole discretion.
		

		
			8.17Releases.
		

		
			(a)At such time as the Secured Obligations have been Paid in Full, the Collateral shall be automatically released from the Liens created hereby, and this Agreement and
		

		
			
		

		
			

		 

		

			-27-

		

		

			 

		

		

		
			 
		

		
			all obligations (other than those expressly stated to survive such termination) of Lender and each Grantor hereunder shall terminate automatically, all without delivery of any instrument or performance of any act by any party, and all rights to the Collateral shall revert to the Grantors. At the request and sole expense of any Grantor following any such termination, Lender shall promptly deliver to the Grantors any Collateral held by Lender hereunder, and execute and deliver to the Grantors such filings and documents (including authorization to file applicable UCC termination statements) as the Grantors shall reasonably request to evidence such termination.
		

		
			(b)If any of the Collateral shall be sold, transferred or otherwise disposed of by any Grantor in a transaction permitted by the Credit Agreement, then the Lender’s Lien on such Collateral pursuant to this Agreement and the other Loan Documents shall automatically terminate and Lender, at the request and sole expense of such Grantor, shall execute and deliver to such Grantor all releases or other documents reasonably necessary or desirable to evidence the release of the Liens created hereby on such Collateral, so long as Borrower delivers to Lender a certificate of an officer of Borrower as to such sale or disposition being made in compliance with the Loan Documents. A Subsidiary Guarantor shall be automatically released from its obligations hereunder in the event that all the equity interests of such Subsidiary Guarantor shall be sold, transferred or otherwise disposed of in a transaction permitted by the Credit Agreement; provided that Borrower shall have delivered to Lender, with reasonable notice prior to the date of the proposed release, a written request for release identifying the relevant Subsidiary Guarantor and the terms of the sale or other disposition in reasonable detail, including the price thereof and any expenses in connection therewith, and, to the extent that Lender is requested to confirm such release or execute any documents in connection therewith, Borrower shall provide Lender with a certification by Borrower stating that such transaction is in compliance with the Credit Agreement and the other Loan Documents and any of the foregoing shall be at the sole expense of Borrower.
		

		
			8.18Obligations and Liens Absolute and Unconditional. Each Grantor understands and agrees that the obligations of each Grantor under this Agreement shall be construed as a continuing, absolute and unconditional without regard to (a) the validity or enforceability of any Loan Document, any of the Secured Obligations or any other collateral security therefor or guaranty or right of offset with respect thereto at any time or from time to time held by Lender, (b) any defense, set-off or counterclaim (other than a defense of payment or performance) which may at any time be available to or be asserted by any Grantor or any other Person against Lender, or (c) any other circumstance whatsoever (with or without notice to or knowledge of any Grantor) which constitutes, or might be construed to constitute, an equitable or legal discharge of any Grantor for the Secured Obligations, in bankruptcy or in any other instance (other than a defense of payment or performance).  When making any demand hereunder or otherwise pursuing its rights and remedies hereunder against any Grantor, Lender may, but shall be under no obligation to, make a similar demand on or otherwise pursue such rights and remedies as it may have against any other Grantor or any other Person or against any collateral security or guaranty for the Secured Obligations or any right of offset with respect thereto, and any failure by Lender to make any such demand, to pursue such other rights or remedies or to collect any payments from any other Grantor or any other Person or to realize upon any such collateral security or guaranty or to exercise any such right of offset, or any release of any other Grantor or any other Person or any such collateral security, guaranty or right of offset, shall not relieve any Grantor of any obligation or liability hereunder, and shall not impair or affect the rights and remedies, whether express, implied or
		

		
			
		

		
			

		 

		

			-28-

		

		

			 

		

		

		
			 
		

		
			available as a matter of law, of Lender against any Grantor. For the purposes hereof “demand” shall include the commencement and continuance of any legal proceedings.
		

		
			8.19Reinstatement. This Agreement shall remain in full force and effect and continue to be effective should any petition be filed by or against Grantor or any Issuer for liquidation or reorganization,  should Grantor or any Issuer become insolvent or make an assignment for the benefit of creditors or should a receiver or trustee be appointed for all or any significant part of Grantor’s or any Issuer’s assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Secured Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Secured Obligations, whether as a ”voidable preference”, ”fraudulent conveyance”, or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Secured Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.
		

		
			[signature page follows]
		

		
			 
		

		
			
		

		
			

		 

		

			-29-

		

		

			 

		

		

		
			 
		

		
			Each of the undersigned has caused this Guarantee and Collateral Agreement to be duly executed and delivered as of the date first above written.
		

		
			 
		

			
					
						 

					
					
						RESHAPE LIFESCIENCES INC., a Delaware corporation, as Grantor

				
	
					
						 

					
					
						 

				
	
					
						 

					
						 

					
					
						By:      /s/ Barton P. Bandy

					
					
						 

				
	
					
						Name: Barton P. Bandy

					
					
						 

				
	
					
						Title:   CEO      

				
	
					
						 

				

		
			 
		

		
			
		

		
			

		 

		

			-30-

		

		

			 

		

		

		
			 
		

			
					
						 

					
					
						RESHAPE MEDICAL LLC, a Delaware limited liability company, as Grantor

				
	
					
						 

					
					
						 

				
	
					
						 

					
						 

					
					
						By:      /s/ Barton P. Bandy

					
					
						 

				
	
					
						Name: Barton P. Bandy

					
					
						 

				
	
					
						Title:   CEO   

				
	
					
						 

				

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			
		

		
			

		 

		

			-31-

		

		

			 

		

		

		
			 
		

			
					
						 

					
					
						ARMISTICE CAPITAL MASTER FUND LTD., as Lender

				
	
					
						 

					
					
						 

				
	
					
						 

					
						 

					
					
						By:      /s/ Steven Boyd

					
					
						 

				
	
					
						Name: Steven Boyd

					
					
						 

				
	
					
						Title:   CIO of Armistice Capital, LLC, the Investment Manager

				
	
					
						 

				

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			-32-

		

		

		
			 
		

		
			SCHEDULE 1
		

		
			TO
		

		
			COLLATERAL AND SECURITY AGREEMENT
		

		
			 
		

		
			Pledged Equity and Pledged Notes
		

		
			 
		

		
			100% of the membership interests of ReShape Medical LLC, a Delaware limited liability company
		

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			Schedule 1-1

		

		

			 

		

		

		
			 
		

		
			SCHEDULE 2
		

		
			TO
		

		
			COLLATERAL AND SECURITY AGREEMENT
		

		
			 
		

		
			Perfected First Priority Liens
		

		
			None
		

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			Schedule 2-1

		

		

			 

		

		

		
			SCHEDULE 3 
		

		
			TO
		

		
			GUARANTEE AND COLLATERAL AGREEMENT
		

		
			 
		

		
			Grantor Information
		

		
			 
		

		
			 
		

			
					
						Name of
Grantor

					
					
						Jurisdiction of
Organization

					
					
						Office Locations

					
					
						Federal EIN

					
					
						Organization
Number

				
	
					
						ReShape Lifesciences Inc.

					
					
						Delaware

					
					
						1001 Calle Amanecer

					
						San Clemente, CA 92673

					
					
						48-1293684

					
					
						3832130

				
	
					
						ReShape Medical LLC

					
					
						Delaware

					
					
						1001 Calle Amanecer

					
						San Clemente, CA 92673

					
					
						82-3076787

					
					
						6561638

				

		
			 
		

		
			 
		

		
			

		 

		

			Schedule 3-1

		

		

			 

		

		

		
			SCHEDULE 4
		

		
			TO
		

		
			GUARANTEE AND COLLATERAL AGREEMENT
		

		
			 
		

		
			Locations of Equipment and Inventory
		

		
			 
		

		
			 
		

			
					
						Name of Grantor

					
					
						Locations of Equipment and Inventory

				
	
					
						ReShape  Lifesciences Inc.

					
					
						1001 Calle Amanecer 

					
						San Clemente, CA 92673

					
						This is a leased facility. Landlord’s notice address is: San Clemente Holdings, LLC

					
						P.O. Box 74268, San Clemente, CA 92673

				
	
					
						ReShape Medical LLC

					
					
						1001 Calle Amanecer

					
						San Clemente, CA 92673

				

		
			 
		

		
			

		 

		

			Schedule 4-1

		

		

			 

		

		

		
			SCHEDULE 5
		

		
			TO
		

		
			GUARANTEE AND COLLATERAL AGREEMENT
		

		
			 
		

		
			Patents and Registered IP
		

		
			 
		

		
			See attached for the list of Borrower’s patents and patent applications.
		

		
			 
		

		
			Also, in the United States the Borrower has registered trademarks for LAP-BAND®, LAP-BAND AP®, LAP BAND SYSTEM®, RAPIDPORT®, RESHAPE® and RESHAPE MEDICAL® and trademark applications for RESHAPE VEST, and RESHAPE LIFESCIENCES.
		

		
			
		

		

		 

		

			Schedule 5-1

		

		

			 

		

	
					
						

					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						74660-00100

					
						US Utility

					
					
						Reshape Lifesciences, Inc.

					
					
						Method and Apparatus for Gastric Restriction of the Stomach to Treat Obesity

					
					
						Raj Nihalani

					
					
						12/328,979

					
						12/5/2008

					
					
						8,357,081

					
						1/22/2013

					
					
						Issued

					
						MaintenanceFee Due 7/22/2020

				
	
					
						74660-00117

					
						US Utility

					
					
						Reshape Lifesciences, Inc.

					
					
						Gastric Restriction Devices with Fillable Chambers and Ablation Means for Treating

					
						Obesity

					
					
						Raj Nihalani

					
					
						12/474,254

					
						5/28/2009

					
					
						8,911,346

					
						12/16/2014

					
					
						Issued

					
						MaintenanceFee Due 6/16/2022

				
	
					
						74660-00138

					
						US Utility

					
					
						ReShape Lifesciences, Inc.

					
					
						Gastric Restriction Devices for Treating Obesity

					
					
						Raj Nihalani

					
					
						14/571,144

					
						12/15/2014

					
					
						10,010,441

					
						7/3/20189

					
					
						Issued

					
						MaintenanceFee Due 1/3/2022

				
	
					
						74660-00139

					
						US Utility

					
					
						ReShape Lifesciences, Inc.

					
					
						Gastric Restriction Devices for Treating Obesity

					
					
						Raj Nihalani

					
					
						16/020,423

					
						6/27/2018

					
					
						 

					
					
						Pending

					
						AwaitingFirst Office Action

				
	
					
						74660-00193

					
						Australia DIV

					
					
						Onciomed, Inc.

					
					
						Gastric Restriction Devices with Fillable Chambers and Ablation Means for Treating Obesity

					
					
						Raj Nihalani

					
					
						2014201234

					
						3/5/2014

					
					
						2014201234

					
						3/31/2016

					
					
						Pending

					
						AnnuityDue 12/2/2020

				
	
					
						74660-00103

					
						Canada

					
					
						Onciomed, Inc.

					
					
						Gastric Restriction Devices with Fillable Chambers and Ablation Means for Treating Obesity

					
					
						Raj Nihalani

					
					
						2745902

					
						12/2/2009

					
					
						2745902

					
						4/19/2016

					
					
						Issued

					
						AnnuityDue 12/02/2020

				

		
			 
		

		
			
		

		
			

		 

		

			Schedule 5--6

		

		

			 

		

		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
						 

					
					
						 

					
						 

					
					
						 

				
	
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						74660-00105

					
						Europe

					
					
						Onciomed, Inc.

					
					
						Gastric Restriction Devices with Fillable Chambers and Ablation Means for Treating Obesity

					
					
						Raj Nihalani

					
					
						09831063.4

					
						12/2/2009

					
					
						2370003

					
						04/17/2019

					
					
						Pending

					
						AnnuityDue 12/2/2020

					
						(validated in DE, FR & UK)

				
	
					
						74660-00109

					
						Israel

					
					
						Onciomed, Inc.

					
					
						Gastric Restriction Devices with Fillable Chambers and Ablation Means for Treating Obesity

					
					
						Raj Nihalani

					
					
						213388

					
						12/2/2009

					
					
						213388

					
						12/1/2014

					
					
						Issued

					
						RenewalDue 12/2/2019

				
	
					
						74660-00128

					
						Brazil

					
					
						Onciomed, Inc.

					
					
						Gastric Restriction Devices with Fillable Chambers and Ablation Means for Treating Obesity

					
					
						Raj Nihalani

					
					
						PI0922794-6 12/2/2009

					
					
						 

					
					
						Pending

					
						AnnuityDue 12/2/2020

				
	
					
						74660-00134

					
						China

					
					
						Onciomed, Inc.

					
					
						Gastric Restriction Devices with Fillable Chambers and Ablation Means for Treating Obesity

					
					
						Raj Nihalani

					
					
						20098015623

					
						4.2

					
						12/2/2009

					
					
						102307530

					
						11/19/2014

					
					
						Issued

					
						AnnuityDue 12/2/2020

				
	
					
						74660-00137

					
						China DIV

					
					
						Onciomed, Inc.

					
					
						Gastric Restriction Devices with Fillable Chambers and Ablation Means for Treating Obesity

					
					
						Raj Nihalani

					
					
						20141053862

					
						7.2

					
						12/2/2009

					
					
						ZL201410538 627.2

					
						3/13/2018

					
					
						Issued

					
						AnnuityDue 12/2/2020

				
	
					
						74660-00156

					
						India

					
					
						Onciomed, Inc.

					
					
						Gastric Restriction Devices with Fillable Chambers and Ablation Means for Treating Obesity

					
					
						Raj Nihalani

					
					
						1381/MUMN P/2011

					
						12/2/2009

					
					
						 

					
					
						Pending

				

		
			 
		

		
			 
		

		

		 

		

			Schedule 5--7

		

		

			 

		

	
					
						

					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
						 

					
					
						 

					
						 

					
					
						 

				
	
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						74660-00616

					
						PCT

					
					
						ReShape Lifesciences, Inc.

					
					
						Gastric Vest for Restriction of the Stomach to Treat Obesity

					
					
						Raj Nihalani Reynz Delina

					
					
						PCT/US2018/ 054434

					
						10/4/2018

					
					
						 

					
					
						(Awaiting Client Final Inst on Country List) Pending 30 Month National Phase Applications Due 4/4/2020

				
	
					
						74660-00600

					
						US

					
					
						ReShape Lifesciences,  Inc.

					
					
						Gastric Vest for Restriction of the Stomach to Treat Obesity

					
					
						Raj Nihalani Reynz Delina

					
					
						16/326,607

					
						2/19/2019

					
					
						 

					
					
						Pending

					
						AwaitingFirst Office Action

				
	
					
						74660-06500

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Fatigue-ResistantGastric Banding Device

					
					
						Janel Birk

					
					
						10/492,784

					
						04/18/2005

					
					
						7,811,298

					
						10/12/2010

					
					
						3rd MFee Due

					
						04/12/2022

				
	
					
						74660-06517

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Fatigue-ResistantGastric Banding Device

					
					
						Janel Birk

					
					
						12/851,437

					
						08/05/2010

					
					
						8,382,780

					
						02/26/2013

					
					
						2nd MFee Due

					
						08/26/2020

				
	
					
						74660-06505

					
						EP

					
					
						Apollo Endosurgery, Inc.

					
					
						Fatigue-ResistantGastric Banding Device

					
					
						Janel Birk

					
					
						10001759

					
						08/26/2003

					
					
						2181655

					
						07/12/2016

					
					
						AnnuitiesDue 08/26/2020

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						(validated in DE, ES, FR, GB)

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						(dropped in DE in 2019)

				
	
					
						74660-06600

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Releasably-Securable One- Piece Adjustable Gastric Band

					
					
						Janel A. Birk

					
					
						10/587,099

					
						12/04/2008

					
					
						8,900,117

					
						12/02/2014

					
					
						2nd MFee Due 06/02/2022

				

		
			 
		

		
			
		

		
			
		

		
			

		 

		

			Schedule 5--8

		

		

			 

		

		

		
			 
		

			
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						74660-06613

					
						Mexico

					
					
						Allergan, Inc.

					
					
						Releasably-Securable One- Piece Adjustable Gastric Band

					
					
						Janel A. Birk

					
					
						2010/003962

					
					
						305609

					
					
						Annuity Due January, 2022

				
	
					
						74660-06603

					
						Canada DIV

					
					
						Apollo Endosurgery, Inc.

					
					
						Releasably-Securable One- Piece Adjustable Gastric Band

					
					
						Janel A. Birk

					
					
						2567161

					
						07/14/2006

					
					
						2567161

					
						03/13/2012

					
					
						AnnuityDue 7/21/2021

				
	
					
						74660-06605

					
						Europe

					
					
						Apollo Endosurgery, Inc.

					
					
						Releasably-Securable One- Piece Adjustable Gastric Band

					
					
						Janel A. Birk

					
					
						2005705872

					
						07/21/2006

					
					
						1706044

					
						10/05/2011

					
					
						Annuities Due 01/21/2021

					
						For ES, FR, GB, & IT

					
						(Validated in AT, BE, CH/LI, DE, ES, FR, GB, IE,

					
						IT, NL, PT, PL)

					
						Abandoned in BE, CH/LI, DE, IE, NL, PT

				
	
					
						74660-06693

					
						Europe DIV

					
					
						Apollo Endosurgery, Inc.

					
					
						Releasably-Securable One- Piece Adjustable Gastric Band

					
					
						Janel A. Birk

					
					
						2011182494

					
						01/21/2005

					
					
						2399528

					
						01/09/2013

					
					
						Annuities Due 01/21/2021

					
						For ES, FR, GB, & IT

					
						(Validated in AT, BE, CH/LI, DE, ES, FR, GB, IE,

					
						IT, NL, PT)

					
						Abandoned in BE, CH/LI, DE, IE,

				

		
			
		

		
			

		 

		

			Schedule 5--9

		

		

			 

		

		

		
			 
		

			
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						NL, PT

				
	
					
						74660-06601

					
						Australia

					
					
						Apollo Endosurgery, Inc.

					
					
						Releasably-Securable One- Piece Adjustable Gastric Band

					
					
						Janel A. Birk

					
					
						2005208721

					
						08/22/2006

					
					
						2005208721

					
						01/06/2011

					
					
						Annuity Due 01/21/2021

				
	
					
						74660-06622

					
						Mexico

					
					
						Allergan, Inc.

					
					
						Releasably-Securable One- Piece Adjustable Gastric Band

					
					
						Janel A. Birk

					
					
						2006/008256

					
						07/20/2006

					
					
						275168

					
						04/14/2010

					
					
						Annuity Due January, 2021

				
	
					
						74660-06700

					
					
						ApolloEndosurgery US,

					
					
						ImplantableDevice

					
					
						 

					
					
						10/562,964

					
					
						7,762,998

					
					
						3rd MFee Due

				
	
					
						US

					
					
						Inc.

					
					
						FasteningSystemand Methods of Use

					
					
						12/30/2005

					
					
						07/27/2010

					
					
						01/27/2021

				
	
					
						74660-06717

					
					
						ApolloEndosurgery US,

					
					
						ImplantableDevice

					
					
						 

					
					
						12/483,980

					
					
						7,947,011

					
					
						3rd MFee Due

				
	
					
						US CON

					
					
						Inc.

					
					
						FasteningSystemand Methods of Use

					
					
						06/12/2009

					
					
						05/24/2011

					
					
						11/24/2022

				
	
					
						74660-06736

					
					
						ApolloEndosurgery US,

					
					
						ImplantableDevice

					
					
						 

					
					
						12/488,266

					
					
						7,972,315

					
					
						3rd MFee Due

				
	
					
						US CON2

					
					
						Inc.

					
					
						FasteningSystemand Methods of Use

					
					
						06/19/2009

					
					
						07/05/2011

					
					
						01/05/2023

				
	
					
						74660-06738

					
						US CON3

					
					
						ApolloEndosurgery US, Inc.

					
					
						Methods of Implanting an Injection Port

					
					
						 

					
					
						12/488,364

					
						06/19/2009

					
					
						7,811,275

					
						10/12/2010

					
					
						3rd MFee Due

					
						04/12/2022

				
	
					
						74660-06739

					
						US CON4

					
					
						Reshape Lifesciences Inc.

					
					
						Implantable Injection Port

					
					
						Janel A. Birk; Frederick L. Coe; Robert E. Hoyt

					
					
						12/488/421

					
						06/19/2009

					
					
						8,007,479

					
						08/30/2011

					
					
						3rdMFeeDue 02/28/2023

				

		
			 
		

		
			
		

		
			

		 

		

			Schedule 5--10

		

		

			 

		

		

		
			 
		

			
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						74660-06793

					
						US CON5

					
					
						Reshape Lifesciences Inc.

					
					
						ImplantableDevice Fastening System and Methods of Use

					
					
						Janel A. Birk; Frederick L. Coe; Robert E. Hoyt

					
					
						12/488,496

					
						06/19/2009

					
					
						8,007,465

					
						08/30/2011

					
					
						4rd MFee Fee Due 08/28/2023

				
	
					
						74660-06794

					
					
						ApolloEndosurgery US,

					
					
						ImplantableDevice

					
					
						 

					
					
						12/548/703

					
					
						7,892,200

					
					
						3rd MFee Due

				
	
					
						US CON6

					
					
						Inc.

					
					
						FasteningSystemand Methods of Use

					
					
						08/27/2009

					
					
						02/22/2011

					
					
						08/22/2022

				
	
					
						74660-06795

					
						US CIP

					
					
						ApolloEndosurgery US, Inc.

					
					
						Methods of Operating an Implantable Injection Port System

					
					
						Janel A. Birk,

					
						FrederickL. Coe,

					
					
						12/607,283

					
						10/28/2009

					
					
						8,079,989

					
						12/20/2011

					
					
						3rd MFee Due

					
						6/20/2023

				
	
					
						 

					
					
						 

					
					
						 

					
					
						Robert E. Hoyt

					
					
						 

					
					
						 

					
					
						 

				
	
					
						74660-06796

					
						US CIP2

					
					
						ApolloEndosurgery US, Inc.

					
					
						ImplantableMedical Implants Having Fasteners and Methods of Fastening

					
					
						 

					
					
						12/607,323

					
						10/28/2009

					
					
						8,409,203

					
						04/02/2013

					
					
						2nd MFee Due

					
						10/02/2020

				
	
					
						74660-06797

					
					
						ApolloEndosurgery US,

					
					
						ImplantableDevice

					
					
						 

					
					
						12/843,629

					
					
						8,496,614

					
					
						2nd MFee Due

				
	
					
						US CON7

					
					
						Inc.

					
					
						Fastening System

					
					
						07/26/2010

					
					
						07/30/2013

					
					
						01/30/2021

				
	
					
						74660-06798

					
					
						ApolloEndosurgery US,

					
					
						ImplantableDevice

					
					
						 

					
					
						13/159,883

					
					
						8,317,761

					
					
						2nd MFee Due

				
	
					
						US CON8

					
					
						Inc.

					
					
						FasteningSystemand Methods of Use

					
					
						06/14/2011

					
					
						11/27/2012

					
					
						05/27/2020

				
	
					
						74660-06701

					
						Australia

					
					
						Apollo Endosurgery, Inc.

					
					
						ImplantableDevice Fastening System and Methods of Use

					
					
						 

					
					
						2004281641

					
						09/15/2004

					
					
						2004281641

					
						09/30/2010

					
					
						AnnuityDue 09/15/2020

				
	
					
						74660-06799

					
						Australia DIV

					
					
						Apollo Endosurgery, Inc.

					
					
						ImplantableDevice Fastening System and Methods of Use

					
					
						 

					
					
						2010201790

					
						05/04/2010

					
					
						2010201790

					
						03/14/2013

					
					
						Annuity Due 09/15/2020

				

		
			 
		

		

		 

		

			Schedule 5--11

		

		

			 

		

	
					
						

					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						74660-06705

					
						Europe

					
					
						Apollo Endosurgery, Inc.

					
					
						ImplantableDevice Fastening System

					
					
						 

					
					
						2004788749

					
					
						1662971

					
						06/22/2011

					
					
						AnnuitiesDue 09/30/2020

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						(Validated in DE, FR, GB, & IT)

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						Dropped in DE

				
	
					
						74660-06765

					
						Europe DIV

					
					
						Apollo Endosurgery, Inc.

					
					
						ImplantableDevice Fastening System and Methods of Use

					
					
						 

					
					
						2011152489

					
					
						2311520

					
						12/03/2014

					
					
						Annuities Due 09/30/2020

					
						(Validated in BE, DE. FR, GB, IT)

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						Dropped in BE & DE

				
	
					
						74660-06713

					
					
						Allergan, Inc.

					
					
						ImplantableDevice

					
					
						 

					
					
						PA06003005

					
					
						265727

					
					
						Annuity Due

				
	
					
						Mexico

					
					
						 

					
					
						FasteningSystemand Methods of Use

					
					
						03/15/2006

					
					
						04/06/2009

					
					
						September, 2023

				
	
					
						74660-06800

					
					
						ApolloEndosurgery US,

					
					
						ImplantableDevice

					
					
						 

					
					
						10/562,954

					
					
						7,901,381

					
					
						3rd MFee Due

				
	
					
						US

					
					
						Inc.

					
					
						FasteningSystemand Methods of Use

					
					
						12/30/2005

					
					
						03/08/2011

					
					
						09/08/2022

				
	
					
						74660-06803

					
						Canada

					
					
						Apollo Endosurgery, Inc.

					
					
						ImplantableDevice Fastening System and Methods of Use

					
					
						 

					
					
						2567158

					
						07/07/2006

					
					
						2567158

					
						08/09/2011

					
					
						AnnuityDue 7/21/2021

				
	
					
						74660-06801

					
						Australia

					
					
						Apollo Endosurgery, Inc.

					
					
						ImplantableDevice Fastening System and Methods of Use

					
					
						 

					
					
						2005209251

					
						07/20/2006

					
					
						2005209251

					
						05/20/2010

					
					
						AnnuityDue 01/21/2021

				
	
					
						74660-06805

					
						Europe

					
					
						Apollo Endosurgery, Inc.

					
					
						ImplantableDevice FasteningSystemand

					
					
						 

					
					
						200570596

					
						12/22/2005

					
					
						1670362

					
						12/01/2010

					
					
						Annuities Due

					
						01/21/2021 for

				

		
			 
		

		
			
		

		
			

		 

		

			Schedule 5--12

		

		

			 

		

		

		
			 
		

			
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						 

					
					
						 

					
					
						Methods of Use

					
					
						 

					
					
						 

					
					
						 

					
					
						ES, FR, GB, & IT

					
						(Validated in DE, ES, FR, GB, IT, & TR)

					
						Abandoned in DE and TR

				
	
					
						74660-06893

					
						Australia DIV

					
					
						Apollo Endosurgery, Inc.

					
					
						ImplantableDevice Fastening System and Methods of Use

					
					
						 

					
					
						2010201793

					
						05/04/2010

					
					
						2010201793

					
						12/13/2012

					
					
						AnnuityDue 01/21/2021

				
	
					
						74660-06895

					
						Europe DIV

					
					
						Apollo Endosurgery, Inc.

					
					
						ImplantableDevice Fastening System

					
					
						 

					
					
						2010181580

					
						01/21/2005

					
					
						2260773

					
						12/21/2011

					
					
						AnnuitiesDue 01/21/2021 for

					
						ES, FR, GB, & IT

					
						(Validated in DE, ES, FR, GB, & IT)

					
						Abandoned in DE

				
	
					
						74660-06896

					
						Europe DIV

					
					
						Apollo Endosurgery, Inc.

					
					
						ImplantableDevice Fastening System

					
					
						 

					
					
						2011194523

					
					
						2433672

					
					
						Annuities Due

					
						01/21/2021for ES, FR, GB, & IT

					
						(Validated in DE, ES, FR, GB, & IT)

					
						Abandoned in DE

				
	
					
						74660-06900

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Implantable Access Port Device and Attachment System

					
					
						 

					
					
						12/426,057

					
						04/17/2009

					
					
						9,023,062

					
						05/05/2015

					
					
						2nd MFee Due

					
						11/05/2022

				

		
			 
		

		
			
		

		
			

		 

		

			Schedule 5--13

		

		

			 

		

		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
						 

					
					
						 

					
						 

					
					
						 

				
	
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						74660-06917

					
						US CON

					
					
						ApolloEndosurgery US, Inc.

					
					
						ImplantableAccessPort Device Having a Safety Cap

					
					
						 

					
					
						12/750,565

					
						03/30/2010

					
					
						9,023,063

					
						05/05/2015

					
					
						2nd MFee Due

					
						11/05/2022

				
	
					
						74660-06936

					
						US DIV

					
					
						ApolloEndosurgery US, Inc.

					
					
						ImplantableAccessPort Device Having a Safety Cap

					
					
						 

					
					
						13/546,204

					
						07/11/2012

					
					
						8,409,221

					
						04/02/2013

					
					
						2nd MFee Due

					
						10/02/2020

				
	
					
						74660-06937

					
						US CON2

					
					
						ApolloEndosurgery US, Inc.

					
					
						Implantable Access Port Device and Attachment System

					
					
						 

					
					
						13/088,966

					
						04/18/2011

					
					
						8,398,654

					
						03/19/2013

					
					
						2nd MFee Due

					
						09/19/2020

				
	
					
						74660-06913

					
						Mexico

					
					
						Allergan, Inc.

					
					
						Implantable Access Port Device and Attachment System

					
					
						 

					
					
						MX/a/2010/0 11367

					
					
						317903

					
					
						AnnuityDue April, 2024

				
	
					
						74660-07000

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						SystemIncludingAccess Port and Applicator Tool

					
					
						 

					
					
						12/772,039

					
						04/30/2010

					
					
						8,506,532

					
						08/13/2013

					
					
						2nd MFee Due

					
						02/13/2021

				
	
					
						74660-07005

					
						Europe

					
					
						Apollo Endosurgery, Inc.

					
					
						SystemIncludingAccess Port and Applicator Tool

					
					
						CraigOlroyd; Christopher Mudd;Ahmet Tezel;Kris Turner;

					
					
						2010745073

					
						03/23/2012

					
					
						2470128

					
						07/20/2016

					
					
						AnnuitiesDue 08/10/2020

					
						(Validated in DE, ES, FR, & GB)

					
						(dropped in DE in 2019)

				
	
					
						74660-07100

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Self-Adjusting Gastric Band

					
					
						 

					
					
						13/216,132

					
						08/23/2011

					
					
						9,044,298

					
						06/02/2015

					
					
						2nd MFee Due

					
						12/02/2022

				
	
					
						74660-07200

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Self-Adjusting Gastric Band Having Various Complaint Components and/or a  Satiety Booster

					
					
						 

					
					
						13/934,987

					
						07/03/2013

					
					
						9,295,573

					
						03/29/2016

					
					
						Abandoned 2/21/2020

				

		
			 
		

		
			
		

		
			

		 

		

			Schedule 5--14

		

		

			 

		

		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
						 

					
					
						 

					
						 

					
					
						 

				
	
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						74660-07300

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Implantable Device to Protect Tubing From Puncture

					
					
						 

					
					
						12/771,609

					
						04/30/2010

					
					
						8,992,415

					
						03/31/2015

					
					
						2nd Mfee Due

					
						09/30/2022

				
	
					
						74660-07400

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Flow Control Method and Device

					
					
						 

					
					
						10/031,469

					
						05/29/2002

					
					
						7,128,750

					
						10/31/2006

					
					
						All Mfees

					
						Paid

				
	
					
						74660-07417

					
						US CON

					
					
						ApolloEndosurgery US, Inc.

					
					
						Flow Control Method and Device

					
					
						Nikos Stergiopulos

					
					
						11/586,886

					
						10/26/2006

					
					
						8,079,974

					
						12/20/2011

					
					
						Abandoned 11/22/19

				
	
					
						74660-07436

					
						US CON2

					
					
						ApolloEndosurgery US, Inc.

					
					
						Flow Control Method and Device

					
					
						 

					
					
						13/018,270

					
						01/31/2011

					
					
						8,932,247

					
						01/13/2015

					
					
						2nd Mfee Due

					
						07/13/2022

				
	
					
						74660-07437

					
						US CON3

					
					
						ApolloEndosurgery US, Inc.

					
					
						Flow Control Method and Device

					
					
						 

					
					
						13/036,358

					
						02/28/2011

					
					
						8,506,517

					
						08/13/2013

					
					
						2nd Mfee Due

					
						02/15/2021

				
	
					
						74660-07438

					
						US CON4

					
					
						ApolloEndosurgery US, Inc.

					
					
						Flow Control Method and Device

					
					
						 

					
					
						13/184,340

					
						07/15/2011

					
					
						8,821,430

					
						09/02/2014

					
					
						2nd Mfee Due

					
						03/02/2022

				
	
					
						74660-07500

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Surgical Ring Featuring a ReversibleDiameter Remote Control System (mechanically operable RAB with helical screw or spring within and fixed to one end of the band)

					
					
						 

					
					
						10/653,808

					
						09/03/2003

					
					
						7,238,191

					
						07/03/2007

					
					
						All Mfees Paid

				

		
			 
		

		
			
		

		
			

		 

		

			Schedule 5--15

		

		

			 

		

		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
						 

					
					
						 

					
						 

					
					
						 

				
	
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						74660-07517

					
						US CIP

					
					
						ApolloEndosurgery US, Inc.

					
					
						Telemetrically Controlled Band for Regulating Functioning of a Body Organ or Duct, and Methods of Making, Implantation and Use

					
					
						 

					
					
						10/962,939

					
						10/12/2004

					
					
						7,972,346

					
						07/05/2011

					
					
						3rdMfee

					
						01/05/2023

				
	
					
						74660-07513

					
						Mexico

					
					
						Endorat S.A.

					
					
						Telemetrically Controlled Band for Regulating Functioning of a Body Organ or Duct, and Methods of Making, Implantation and Use

					
					
						 

					
					
						MX/a/2007/0 04338

					
					
						287691

					
					
						Annuity Due October, 2021

				
	
					
						74660-07700

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Closure System for Tubular Organs

					
					
						 

					
					
						12/874,147

					
						09/01/2010

					
					
						8,377,081

					
						02/19/2013

					
					
						2nd Mfee Due

					
						08/19/2020

				
	
					
						74660-07917

					
						US CON

					
					
						ApolloEndosurgery US, Inc.

					
					
						HydraulicGastricBand With Collapsible Reservoir

					
					
						 

					
					
						13/184,456

					
						07/15/2011

					
					
						8,323,180

					
						12/04/2012

					
					
						2nd Mfee Due

					
						06/04/2020

				
	
					
						74660-08100

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Implantable Pump System with Calibration

					
					
						 

					
					
						12/500,464

					
						07/09/2009

					
					
						8,376,929

					
						02/19/2013

					
					
						2nd Mfee Due

					
						08/19/2020

				
	
					
						74660-08200

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Electrically Activated Valve for Implantable Fluid Handling System

					
					
						 

					
					
						12/603,058

					
						10/21/2009

					
					
						8,366,602

					
						02/05/2013

					
					
						2nd Mfee Due 08/05/2020

				
	
					
						74660-08300

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						MechanicalGastricBand With Cushions (Easy Band)

					
					
						 

					
					
						12/574,640

					
						10/06/2009

					
					
						8,317,677

					
						11/27/2012

					
					
						2nd Mfee Due

					
						05/27/2020

				
	
					
						74660-08400

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						RemotelyAdjustable Gastric Banding System

					
					
						 

					
					
						12/813,355

					
						06/10/2010

					
					
						8,517,915

					
						08/27/2013

					
					
						2nd Mfee Due

					
						02/27/2021

				

		
			 
		

		
			
		

		
			

		 

		

			Schedule 5--16

		

		

			 

		

		

		
			 
		

			
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						74660-09400

					
						US

					
					
						Reshape Lifesciences Inc.

					
					
						Implantable Injection Port

					
					
						Ethan Franklin Justin Schwab

					
						ZacharyP. Dominguez

					
					
						13/277,802

					
						10/20/2011

					
					
						9,199,069

					
						12/01/2015

					
					
						2nd Mfee Due

					
						6/01/2023

				
	
					
						74660-09500

					
						US

					
					
						ApolloEndosurgery US, Inc.

					
					
						Pre-Loaded Septum for Use With an Access Port

					
					
						 

					
					
						13/298,247

					
						11/16/2011

					
					
						9,089,395

					
						07/28/2015

					
					
						2ndMFeeDue 01/28/2023

				
	
					
						74660-11100

					
						US

					
					
						Reshape Lifesciences Inc.

					
					
						Implantable Device

					
					
						 

					
					
						10/506,790

					
						09/07/2004

					
					
						7,314,443

					
						01/01/2008

					
					
						No Fees Due

				
	
					
						74660-11117

					
						US CON

					
					
						ApolloEndosurgery US, Inc.

					
					
						Implantable Device

					
					
						 

					
					
						11/968,012

					
						12/31/2007

					
					
						7,959,552

					
						06/14/2011

					
					
						3rd MFee Due

					
						12/14/2022

				
	
					
						74660-11105

					
						Europe

					
					
						Apollo Endosurgery, Inc.

					
					
						Implantable Device

					
					
						 

					
					
						2003714786

					
						03/06/2003

					
					
						1483730

					
						10/19/2005

					
					
						Annuities Due 03/20/2021

					
						Validated in DE,  ES, FR, UK, & I  T)

					
						Dropped in DE

				
	
					
						74660-11205

					
						Europe

					
					
						Apollo Endosurgery, Inc.

					
					
						ImplantableAccessPort System

					
					
						 

					
					
						20110758065

					
					
						2616134

					
						11/18/2015

					
					
						AnnuitiesDue 09/30/2020

					
						Validated in FR & GB

				
	
					
						74660-11300

					
						US

					
					
						ReShape Lifesciences Inc.

					
					
						Adaptive Reservoir System for a Gastric Device

					
					
						 

					
					
						 

					
					
						 

					
					
						Not Yet Filed

				

		
			 
		

		
			
		

		
			

		 

		

			Schedule 5--17

		

		

			 

		

		

		
			 
		

			
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						US

					
					
						 

					
					
						Obesity Treatment with Electrically Induced Vagal Downregulation

					
					
						 

					
					
						 

					
					
						7,167,750

					
						01/23/2007

					
					
						 

				
	
					
						US

					
					
						 

					
					
						IntraluminalElectrode Apparatus and Method

					
					
						 

					
					
						 

					
					
						7,444,183

					
						10/28/2008

					
					
						 

				
	
					
						US

					
					
						 

					
					
						VagalDown-Regulation Obesity Treatment

					
					
						 

					
					
						 

					
					
						7,489,969

					
						02/10/2009

					
					
						 

				
	
					
						US

					
					
						 

					
					
						HighFrequencyVagal Blockage Therapy

					
					
						 

					
					
						 

					
					
						7,613,515

					
						11/03/2009

					
					
						 

				
	
					
						US

					
					
						 

					
					
						GIInflammatoryDisease Treatment

					
					
						 

					
					
						 

					
					
						7,630,769

					
						12/08/2009

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Neural Electrode Treatment

					
					
						 

					
					
						 

					
					
						7,672,727

					
						03/02/2010

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Irritable Bowel Syndrome Treatment

					
					
						 

					
					
						 

					
					
						7,693,577

					
						04/06/2010

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Pancreatitis Treatment

					
					
						 

					
					
						 

					
					
						7,720,540

					
						05/18/2010

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Nerve Stimulation and Blocking for Treatment of Gastrointestinal Disorders

					
					
						 

					
					
						 

					
					
						7,729,771

					
						06/01/2010

					
					
						 

				
	
					
						US

					
					
						 

					
					
						CustomSizedNeural Electrodes

					
					
						 

					
					
						 

					
					
						7,822,486

					
						10/26/2010

					
					
						 

				

		
			 
		

		
			
		

		
			

		 

		

			Schedule 5--18

		

		

			 

		

		

		
			 
		

			
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						US

					
					
						 

					
					
						RemoteMonitoringand Control of Multiple Devices

					
					
						 

					
					
						 

					
					
						8,068,918

					
						11/29/2011

					
					
						 

				
	
					
						US

					
					
						 

					
					
						ImplantableTherapy System with External ComponentHaving Multiple Operating Modes

					
					
						 

					
					
						 

					
					
						8,140,167

					
						03/20/2012

					
					
						 

				
	
					
						US

					
					
						 

					
					
						ImplantableDevicewith Heat Storage

					
					
						 

					
					
						 

					
					
						8,326,426

					
						12/04/2012

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Bulimia Treatment

					
					
						 

					
					
						 

					
					
						8,369,952

					
						02/05/2013

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Methods and Systems for Glucose Regulation

					
					
						 

					
					
						 

					
					
						8,483,830

					
						07/09/2013

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Antenna Arrangements for Implantable Therapy Device

					
					
						 

					
					
						 

					
					
						8,483,838

					
						07/09/2013

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Remote Monitoring and Control of Implantable Devices

					
					
						 

					
					
						 

					
					
						8,521,299

					
						08/27/2013

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Implantable Therapy system Having Multiple Operating Modes

					
					
						 

					
					
						 

					
					
						8,532,787

					
						09/10/2013

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Controlled Vagal Blockage Therapy

					
					
						 

					
					
						 

					
					
						8,538,533

					
						09/17/2013

					
					
						 

				

		
			 
		

		
			
		

		
			

		 

		

			Schedule 5--19

		

		

			 

		

		

		
			 
		

			
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						US

					
					
						 

					
					
						Nerve Stimulation and Blocking for Treatment of Gastrointestinal Disorders

					
					
						 

					
					
						 

					
					
						8,538,542

					
						09/17/2013

					
					
						 

				
	
					
						US

					
					
						 

					
					
						ObesityTreatmentand Device

					
					
						 

					
					
						 

					
					
						8,372,158

					
						02/12/2013

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Systems for Regulation of Blood Pressure and Heart Rate

					
					
						 

					
					
						 

					
					
						8,768,469

					
						07/01/2014

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Neural Modulation Devices and Methods

					
					
						 

					
					
						 

					
					
						8,825,164

					
						09/02/2014

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Electrode Band system and Methods of Using the System to Treat Obesithy

					
					
						 

					
					
						 

					
					
						8,862,233

					
						10/14/2014

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Treatment of Excess Weight by Neural Downregulation in Combinationwith Compositions

					
					
						 

					
					
						 

					
					
						9,186,502

					
						11/17/2015

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Methods and Systems for Glucose Regulation

					
					
						 

					
					
						 

					
					
						9,333,340

					
						05/10/2016

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Neural Modulation Devices and Methods

					
					
						 

					
					
						 

					
					
						9,358,395

					
						06/07/2016

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Safety Features for Use in Medical Devices

					
					
						 

					
					
						 

					
					
						9,393,420

					
						07/19/2016

					
					
						 

				

		
			 
		

		
			
		

		
			

		 

		

			Schedule 5--20

		

		

			 

		

		

		
			 
		

			
					
						DOCKET NO.

					
					
						ASSIGNEE

					
					
						TITLE

					
					
						INVENTOR

					
					
						SERIAL NO.

					
						FILING DATE

					
					
						PATENT NO.

					
						ISSUE DATE

					
					
						STATUS

				
	
					
						US

					
					
						 

					
					
						Electrode Band System and Methods of Using the System to Treat Obesity

					
					
						 

					
					
						 

					
					
						9,586,046

					
						03/07/2017

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Nerve Stimulation and Blocking for Treatment of Gastrointestinal Disorders

					
					
						 

					
					
						 

					
					
						9,682,233

					
						06/20/2017

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Systems for Regulation of Blood Pressure and Heart Rate

					
					
						 

					
					
						 

					
					
						9,616,231

					
						04/11/2017

					
					
						 

				
	
					
						US

					
					
						 

					
					
						System and Method for Managing Mobile Drive Units

					
					
						 

					
					
						 

					
					
						8,068,978

					
						11/29/2011

					
					
						 

				
	
					
						US

					
					
						 

					
					
						ObesityTreatmentand Device

					
					
						 

					
					
						 

					
					
						8,372,158

					
						02/12/2013

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Systems for Regulation of Blood Pressure and Heart Rate

					
					
						 

					
					
						 

					
					
						9,616,231

					
						04/11/2017

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Neural Modulation Devices and Methods

					
					
						 

					
					
						 

					
					
						9,968,778

					
						05/15/2018

					
					
						 

				
	
					
						US

					
					
						 

					
					
						Calibration Methods for Near-FieldAcoustic Imaging Systems

					
					
						 

					
					
						 

					
					
						9,979,955

					
						05/22/2018

					
					
						 

				

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			Schedule 5--21

		

		

			 

		

		

		
			SCHEDULE 6 
		

		
			TO
		

		
			GUARANTEE AND COLLATERAL AGREEMENT
		

		
			 
		

		
			Deposit Accounts
		

		
			 
		

		
			 
		

			
					
						s

					
					
						 

					
					
						 

					
						 

					
					
						 

				
	
					
						Type of Account

					
					
						Depository Bank or
Securities Intermediary

					
					
						Address of Depository Bank
or Securities Intermediary

					
					
						Account Number

				
	
					
						Operating Account

					
					
						Silicon Valley Bank

					
					
						3003 Tasman Drive

					
						Santa Clara, CA 95054

					
					
						3300626746

				

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			Schedule 6-1

		

		

			 

		

		

		
			SCHEDULE 7 
		

		
			TO
		

		
			GUARANTEE AND COLLATERAL AGREEMENT
		

		
			 
		

		
			Commercial Tort Claims
		

		
			 
		

		
			 
		

		
			None.
		

		
			 
		

		 

		

			Schedule-7rsls_Ex10_33

		
			Exhibit 10.33
		

		
			REGISTRATION RIGHTS AGREEMENT
		

		
			 
		

		
			This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 25, 2020, between ReShape Life Sciences, Inc., a Delaware corporation (the “Company”), and the purchaser signatory hereto (the “Purchaser”).
		

		
			 
		

		
			               This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and the Purchaser (the “Purchase Agreement”).
		

		
			 
		

		
			               The Company and the Purchaser hereby agrees as follows:
		

		
			 
		

		
			        1.                  Definitions.
		

		
			 
		

		
			As used in this Agreement, the following terms shall have the following meanings:
		

		
			 
		

		
			           “Advice” shall have the meaning set forth in Section 6(d).
		

		
			 
		

		
			“Commission” means the United States Securities and Exchange Commission.
		

		
			 
		

		
			“Common Stock” means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.
		

		
			 
		

		
			“Effectiveness Date” means, with respect to the Initial Registration Statement required to be filed hereunder, the later of (i) the 90th calendar day following the date hereof (or, in the event of a “full review” by the Commission, the 120th calendar day following the date hereof); provided,  however, that in the event the Company is notified by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such Registration Statement shall be the fifth Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise required above, provided, further, if such Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.
		

		
			 
		

		
			“Effectiveness Period” shall have the meaning set forth in Section 2(a).
		

		
			 
		

		
			“Event” shall have the meaning set forth in Section 2(d).
		

		
			 
		

		
			“Event Date” shall have the meaning set forth in Section 2(d).
		

		
			 
		

		
			“Filing Date” means, with respect to the Initial Registration Statement required hereunder, the 60th calendar day following the date hereof and, with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related to the Registrable Securities.
		

		
			

		 

		

			 

		

		

		
			   
		

		
			“Holder” means the holder of Registrable Securities.
		

		
			 
		

		
			“Indemnified Party” shall have the meaning set forth in Section 5(c).
		

		
			 
		

		
			“Indemnifying Party” shall have the meaning set forth in Section 5(c).
		

		
			 
		

		
			“Initial Registration Statement” means the initial Registration Statement filed pursuant to this Agreement.
		

		
			 
		

		
			“Losses” shall have the meaning set forth in Section 5(a).
		

		
			 
		

		
			“Plan of Distribution” shall have the meaning set forth in Section 2(a).
		

		
			 
		

		
			“Prospectus” means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.
		

		
			  
		

		
			“Registrable Securities” means, as of any date of determination, (a) all Shares, (b) all Warrant Shares then issued and issuable upon exercise of the Warrants (assuming on such date the Warrants are exercised in full without regard to any exercise limitations therein), (c) any additional shares of Common Stock issued and issuable in connection with any anti-dilution provisions in the Purchase Agreement and the Warrants (in each case, without giving effect to any limitations on exercise set forth in the Warrants) and (d) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing; provided, however, that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) for so long as (a) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder in accordance with such effective Registration Statement, (b) such Registrable Securities have been previously sold in accordance with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144, as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent and the Holder.
		

		
			 
		

		
			“Registration Statement” means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration statements 
		

		
			
		

		
			

		 

		

			 

		

		

		
			contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such registration statement.
		

		
			 
		

		
			“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
		

		
			 
		

		
			“Rule 415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
		

		
			 
		

		
			“Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
		

		
			 
		

		
			“Selling Stockholder Questionnaire” shall have the meaning set forth in Section 3(a).
		

		
			 
		

		
			“SEC Guidance” means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission staff and (ii) the Securities Act.
		

		
			 
		

		
			“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
		

		
			 
		

		
			“Series G Warrants” means, collectively, the Series G Common Stock purchase warrants, which Warrants shall be exercisable immediately, subject to the Issuable Maximum, have an exercise price equal to $[_] per share (subject to adjustment as provided therein) and have a term of exercise equal to [__].
		

		
			 
		

		
			 
		

		
			“Trading Day” means a day on which the principal Trading Market is open for trading.
		

		
			 
		

		
			“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).
		

		
			 
		

		
			

		 

		

			 

		

		

		
			“Transfer Agent” means EQ Shareowner Services (f/k/a Wells Fargo Shareowner Services), the current transfer agent of the Company, with a mailing address of 1110 Centre Pointe Curve, Suite 101, Mendota Heights, Minnesota 55120 and a facsimile number of 651-450-4078, and any successor transfer agent of the Company. 
		

		
			 
		

		
			“Warrants” means, collectively, the Series G Warrants.
		

		
			 
		

		
			“Warrant Shares” means the shares of Common Stock issuable upon exercise of the Warrants.
		

		
			 
		

		
			       2.                  Shelf Registration.
		

		
			 
		

		
			(a)     On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in accordance herewith, subject to the provisions of Section 2(e)) and shall contain (unless otherwise directed by the Holder) substantially the “Plan of Distribution” attached hereto as Annex A;  provided,  however, that the Holder shall not be required to be named as an “underwriter” without the Holder’s express prior written consent. Subject to the terms of this Agreement, the Company shall use its best efforts to cause a Registration Statement filed under this Agreement (including, without limitation, under Section 3(c)) to be declared effective under the Securities Act as promptly as possible after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its best efforts to keep such Registration Statement continuously effective under the Securities Act until the date that all Registrable Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the Holder (the “Effectiveness Period”). The Company shall request effectiveness of a Registration Statement as of 5:00 p.m. (New York City time) on a Trading Day. The Company shall immediately notify the Holder by e-mail of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness with the Commission, which shall be the date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 a.m. (New York City time) on the Trading Day after the effective date of such Registration Statement, file a final Prospectus with the Commission as required by Rule 424. Failure to so notify the Holder within one (1) Trading Day of such notification of effectiveness or failure to file a final Prospectus as foresaid shall be deemed an Event under Section 2(d).
		

		
			 
		

		
			

		 

		

			 

		

		

		
			(b)      Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly inform the Holder thereof and use its commercially reasonable efforts to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted to be registered by the Commission, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary offering, subject to the provisions of Section 2(e); with respect to filing on Form S-3 or other appropriate form; provided,  however, that prior to filing such amendment, the Company shall be obligated to use diligent efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation 612.09.
		

		
			 
		

		
			(c)     Notwithstanding any other provision of this Agreement, if the Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing by the Holder, the number of Registrable Securities to be registered on such Registration Statement will be reduced as follows:
		

		
			 
		

			
					
						 

					
					
						a.

					
					
						First, the Company shall reduce or eliminate any securities to be included other than Registrable Securities; and

				

		
			 
		

			
					
						 

					
					
						b.

					
					
						Second, the Company shall reduce Registrable Securities represented by Warrant Shares underlying the Series G Warrants.

				

		
			 
		

		
			In the event of a cutback hereunder, the Company shall give the Holder at least five (5) Trading Days prior written notice along with the calculations as to the Holder’s allotment. In the event the Company amends the Initial Registration Statement in accordance with the foregoing, the Company will use its best efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement, as amended.
		

		
			 
		

		
			(d)     If: (i) the Initial Registration Statement is not filed on or prior to its Filing Date (if the Company files the Initial Registration Statement without affording the Holder the opportunity to review and comment on the same as required by Section 3(a) herein, the Company shall be deemed to have not satisfied this clause (i)), or (ii) the Company fails to file with the Commission a request for acceleration of a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities Act, within five Trading Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration Statement will not be “reviewed” or will not be subject to further review, or (iii) prior to the effective 
		

		
			

		 

		

			 

		

		

		
			date of a Registration Statement, the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the Commission in respect of such Registration Statement within ten (10) calendar days after the receipt of comments by or notice from the Commission that such amendment is required in order for such Registration Statement to be declared effective, or (iv) a Registration Statement registering for resale all of the Registrable Securities is not declared effective by the Commission by the Effectiveness Date of the Initial Registration Statement, or (v) after the effective date of a Registration Statement, such Registration Statement ceases for any reason to remain continuously effective as to all Registrable Securities included in such Registration Statement, or the Holder is otherwise not permitted to utilize the Prospectus therein to resell such Registrable Securities, for more than ten (10) consecutive calendar days or more than an aggregate of fifteen (15) calendar days (which need not be consecutive calendar days) during any 12-month period (any such failure or breach being referred to as an “Event”, and for purposes of clauses (i) and (iv), the date on which such Event occurs, and for purpose of clause (ii) the date on which such five (5) Trading Day period is exceeded, and for purpose of clause (iii) the date which such ten (10) calendar day period is exceeded, and for purpose of clause (v) the date on which such ten (10) or fifteen (15) calendar day period, as applicable, is exceeded being referred to as “Event Date”), then, in addition to any other rights the Holder may have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event shall not have been cured by such date) until the applicable Event is cured, the Company shall pay to the Holder an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate Subscription Amount paid by the Holder pursuant to the Purchase Agreement.  If the Company fails to pay any partial liquidated damages pursuant to this Section in full within seven days after the date payable, the Company will pay interest thereon at a rate of 18% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date such partial liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event. Notwithstanding anything to the contrary contained herein, no liquidated damages shall accrue as to any Registrable Securities that are subject to a cut- back pursuant to Section 2(c) (“Cut Back Shares”) until such date as the Company is able to effect the registration of such Cut Back Shares in accordance with any restrictions required by the Commission. From and after the date that such restrictions are terminated, all of the provisions of this Section 2(d) shall again be applicable to such Cut Back Shares; provided, however, that the Filing Date and Effectiveness Date for the Registration Statement including such Cut Back Shares shall be based on the termination date of such restriction.
		

		
			 
		

		
			(e)     If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such 
		

		
			
		

		
			

		 

		

			 

		

		

		
			time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission.
		

		
			 
		

		
			(f)     Notwithstanding anything to the contrary contained herein, in no event shall the Company be permitted to name the Holder or affiliate of the Holder as an Underwriter without the prior written consent of the Holder.
		

		
			 
		

		
			3.            Registration Procedures.
		

		
			 
		

		
			               In connection with the Company’s registration obligations hereunder, the Company shall:
		

		
			 
		

		
			(a)     Not less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior to the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or deemed to be incorporated therein by reference), the Company shall (i) furnish to the Holder copies of all such documents proposed to be filed, which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review of the Holder, and (ii) cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of counsel to the Holder, to conduct a reasonable investigation within the meaning of the Securities Act. The Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Holder shall reasonably object in good faith, provided that, the Company is notified of such objection in writing no later than five (5) Trading Days after the Holder have been so furnished copies of a Registration Statement or one (1) Trading Day after the Holder has been so furnished copies of any related Prospectus or amendments or supplements thereto. The Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as Annex B (a “Selling Stockholder Questionnaire”) on a date that is not less than two (2) Trading Days prior to the Filing Date or by the end of the fourth (4th) Trading Day following the date on which the Holder receives draft materials in accordance with this Section.
		

		
			  
		

		
			(b)     (i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably possible to the Holder true and complete copies of all correspondence from and to the Commission relating to a Registration Statement (provided that, the Company shall excise any information 
		

		
			
		

		
			

		 

		

			 

		

		

		
			contained therein which would constitute material non-public information regarding the Company or any of its Subsidiaries), and (iv) comply in all material respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of disposition by the Holder as set forth in such Registration Statement as so amended or in such Prospectus as so supplemented.
		

		
			 
		

		
			(c)     If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior to the applicable Filing Date, an additional Registration Statement covering the resale by the Holder of not less than the number of such Registrable Securities.
		

		
			  
		

		
			(d)     Notify the Holder of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether there will be a “review” of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued 
		

		
			
		

		
			

		 

		

			 

		

		

		
			availability of a Registration Statement or Prospectus; provided,  however, that in no event shall any such notice contain any information which would constitute material, non-public information regarding the Company or any of its Subsidiaries.
		

		
			 
		

		
			(e)     Use its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.
		

		
			 
		

		
			(f)     Furnish to the Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such Person, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission, provided that any such item which is available on the EDGAR system (or successor thereto) need not be furnished in physical form.
		

		
			 
		

		
			(g)     Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by the Holder in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).
		

		
			 
		

		
			(h)      Prior to any resale of Registrable Securities by the Holder, use its commercially reasonable efforts to register or qualify or cooperate with the Holder in connection with the registration or qualification (or exemption from the Registration or qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United States as the Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement, provided that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction.
		

		
			 
		

		
			(i)     If requested by the  Holder, cooperate with the Holder to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as the Holder may request.
		

		
			 
		

		
			

		 

		

			 

		

		

		
			(j)     Upon the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances taking into account the Company’s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Company notifies the Holder in accordance with clauses (iii) through (vi) of Section 3(d) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holder shall suspend use of such Prospectus. The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company shall be entitled to exercise its right under this Section 3(j) to suspend the availability of a Registration Statement and Prospectus, subject to the payment of partial liquidated damages otherwise required pursuant to Section 2(d), for a period not to exceed 60 calendar days (which need not be consecutive days) in any 12-month period.
		

		
			 
		

		
			(k)     Otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any supplement or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Holder in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Holder is required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.
		

		
			 
		

		
			(l)     The Company shall use its best efforts to obtain and maintain eligibility for use of Form S-3 (or any successor form thereto) for the registration of the resale of Registrable Securities.
		

		
			 
		

		
			(m)     The Company may require the Holder to furnish to the Company a certified statement as to the number of shares of Common Stock beneficially owned by the Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the Registrable Securities solely because the Holder fails to furnish such information within three Trading Days of the Company’s request, any liquidated damages that are accruing at such time as to the Holder only shall be tolled and any Event that may otherwise occur solely because of such delay shall be suspended as to the Holder only, until such information is delivered to the Company.
		

		
			 
		

		
			

		 

		

			 

		

		

		
			        4.                  Registration Expenses. All fees and expenses incident to the performance of or compliance with, this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses of the Company’s counsel and independent registered public accountants) (A) with respect to filings made with the Commission, (B) with respect to filings required to be made with any Trading Market on which the Common Stock is then listed for trading, and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any broker or similar commissions of the Holder or, except to the extent provided for in the Transaction Documents, any legal fees or other costs of the Holder.
		

		
			 
		

		
			        5.                  Indemnification.
		

		
			 
		

		
			(a)     Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless the Holder, the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each of them, each Person who controls any the Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not 
		

		
			

		 

		

			 

		

		

		
			misleading or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue statements or omissions are based solely upon information regarding the Holder furnished in writing to the Company by the Holder expressly for use therein, or to the extent that such information relates to the Holder or the Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by the Holder expressly for use in a Registration Statement, such Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose) or (ii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), the use by the Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified the Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by the Holder and prior to the receipt by the Holder of the Advice contemplated in Section 6(d). The Company shall notify the Holder promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified person and shall survive the transfer of any Registrable Securities by the Holder in accordance with Section 6(h).
		

		
			 
		

		
			(b)     Indemnification by the Holder. The Holder shall indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information so furnished in writing by the Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus or (ii) to the extent, but only to the extent, that such information relates to the Holder’s information provided in the Selling Stockholder Questionnaire or the proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by the Holder expressly for use in a Registration Statement (it being understood that the Holder has approved Annex A hereto for this purpose), such Prospectus or in any amendment or supplement thereto. In no event shall the liability ofa Holder be greater in amount than the dollar amount of the proceeds (net of all expenses paid by the Holder in connection with any claim relating to this Section 5 and the amount of any damages the Holder has otherwise been required to pay by reason of such untrue statement or omission) received by the Holder upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.
		

		
			

		 

		

			 

		

		

		
			 
		

		
			(c)     Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party.
		

		
			 
		

		
			               An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.
		

		
			 
		

		
			               Subject to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party, provided that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.
		

		
			  
		

		
			

		 

		

			 

		

		

		
			(d)     Contribution. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys’ or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.
		

		
			 
		

		
			               The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. In no event shall the contribution obligation of the  Holder of Registrable Securities be greater in amount than the dollar amount of the proceeds (net of all expenses paid by the Holder in connection with any claim relating to this Section 5 and the amount of any damages the Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.
		

		
			 
		

		
			The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties.
		

		
			 
		

		
			        6.                  Miscellaneous.
		

		
			 
		

		
			(a)          Remedies. In the event of a breach by the Company or by the Holder of its obligations under this Agreement, the Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and the Holder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.
		

		
			 
		

		
			

		 

		

			 

		

		

		
			(b)          No Piggyback on Registrations; Prohibition on Filing Other Registration Statements. Neither the Company nor any of its security holders (other than the Holder in such capacity pursuant hereto) may include securities of the Company in any Registration Statements other than the Registrable Securities. The Company shall not file any other registration statements until all Registrable Securities are registered pursuant to a Registration Statement that is declared effective by the Commission, provided that this Section 6(b) shall not prohibit the Company from filing amendments to registration statements filed prior to the date of this Agreement.
		

		
			 
		

		
			(c)          [RESERVED]
		

		
			 
		

		
			(d)         Discontinued Disposition. By its acquisition of Registrable Securities, the Holder agrees that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), the Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the “Advice”) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company agrees and acknowledges that any periods during which the Holder is required to discontinue the disposition of the Registrable Securities hereunder shall be subject to the provisions of Section 2(d).
		

		
			 
		

		
			(e)          Piggy-Back Registrations. If, at any time during the Effectiveness Period, there is not an effective Registration Statement covering all of the Registrable Securities and the Company shall determine to prepare and file with the Commission a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with the Company’s stock option or other employee benefit plans, then the Company shall deliver to the Holder a written notice of such determination and, if within fifteen days after the date of the delivery of such notice, the Holder shall so request in writing, the Company shall include in such registration statement all or any part of such Registrable Securities the Holder requests to be registered; provided,  however, that the Company shall not be required to register any Registrable Securities pursuant to this Section 6(e) that are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Commission pursuant to the Securities Act or that are the subject of a then effective Registration Statement that is available for resales or other dispositions by the Holder.
		

		
			 
		

		
			(f)          Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the Holder. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered to all of the parties to this Agreement.
		

		
			 
		

		
			(g)          Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set forth in the Purchase Agreement.
		

		
			

		 

		

			 

		

		

		
			 
		

		
			(h)        Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of the Holder. The Company may not assign (except by merger) its rights or obligations hereunder without the prior written consent of the Holder. The Holder may assign its rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the Purchase Agreement.
		

		
			 
		

		
			(i)         No Inconsistent Agreements. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing the rights granted to the Holder in this Agreement or otherwise conflicts with the provisions hereof. Except as set forth on Schedule 6(i), neither the Company nor any of its Subsidiaries has previously entered into any agreement granting any registration rights with respect to any of its securities to any Person that have not been satisfied in full.
		

		
			 
		

		
			(j)          Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.
		

		
			   
		

		
			(k)          Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined in accordance with the provisions of the Purchase Agreement.
		

		
			 
		

		
			(l)           Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.
		

		
			 
		

		
			(m)        Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

		

		
			(n)          Headings. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit or affect any of the provisions hereof.
		

		
			  
		

		
			********************
		

		
			 
		

		
			 
		

		
			(Signature Pages Follow)
		

		
			 
		

		
			   
		

		
			   
		

		
			  
		

		
			               
		

		
			

		 

		

			 

		

IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.
		

		
			 
		

		
			 
		

			
					
						 

					
					
						RESHAPE LIFESCIENCES inc. 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						By: 

					
					
						 /s/ Barton P. Bandy

				
	
					
						 

					
					
						 

					
					
						Name: Barton P. Bandy

				
	
					
						 

					
					
						 

					
					
						Title: Chief Executive Officer

				

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			Name of Holder: _________________________
		

		
			 
		

		
			Signature of Authorized Signatory of Holder:  _____________________
		

		
			 
		

		
			Name of Authorized Signatory: _____________________
		

		
			 
		

		
			Title of Authorized Signatory: _____________________
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						RESHAPE LIFESCIENCES inc. 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						By: 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Name: 

				
	
					
						 

					
					
						 

					
					
						Title: 

				

		
			 
		

		
			Name of Holder: __Armistice Capital Master Fund Ltd.________________________
		

		
			 
		

		
			Signature of Authorized Signatory of Holder:  _/s/ Steven Boyd______________________
		

		
			 
		

		
			Name of Authorized Signatory: Steven Boyd
		

		
			 
		

		
			Title of Authorized Signatory: CIO of Armistice Capital, LLC, the Investment Manager 
		

		
			 
		

		
			 
		

		
			   
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			 

		

Annex A
		

		
			 
		

		
			Plan of Distribution
		

		
			 
		

		
			The Selling Stockholder (the “Selling Stockholder”) of the securities and any of its pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal Trading Market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. The Selling Stockholder may use any one or more of the following methods when selling securities:
		

		
			 
		

			
					
						 

					
					
						●

					
					
						ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

				

		
			 
		

			
					
						 

					
					
						●

					
					
						block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;

				

		
			 
		

			
					
						 

					
					
						●

					
					
						purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

				

		
			 
		

			
					
						 

					
					
						●

					
					
						an exchange distribution in accordance with the rules of the applicable exchange;

				

		
			 
		

			
					
						 

					
					
						●

					
					
						privately negotiated transactions;

				

		
			 
		

			
					
						 

					
					
						●

					
					
						settlement of short sales;

				

		
			 
		

			
					
						 

					
					
						●

					
					
						in transactions through broker-dealers that agree with the Selling Stockholder to sell a specified number of such securities at a stipulated price per security;

				

		
			 
		

			
					
						 

					
					
						●

					
					
						through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

				

		
			 
		

			
					
						 

					
					
						●

					
					
						a combination of any such methods of sale; or

				

		
			 
		

			
					
						 

					
					
						●

					
					
						any other method permitted pursuant to applicable law.

				

		
			 
		

		
			The Selling Stockholder may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”), if available, rather than under this prospectus.
		

		
			   
		

		
			Broker-dealers engaged by the Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage 
		

		
			

		 

		

			 

		

		

		
			commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.
		

		
			 
		

		
			In connection with the sale of the securities or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholder may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholder may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
		

		
			 
		

		
			The Selling Stockholder and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. The Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.
		

		
			 
		

		
			The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.
		

		
			 
		

		
			We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholder without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.
		

		
			 
		

		
			Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholder or any other person. We will make copies 
		

		
			
		

		
			

		 

		

			 

		

		

		
			of this prospectus available to the Selling Stockholder and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).
		

		
			 
		

		
			   
		

		
			 
		

		
			

		 

		

			 

		

Annex B
		

		
			 
		

		
			reshape lifesciences inc.
		

		
			 
		

		
			Selling Stockholder Notice and Questionnaire
		

		
			 
		

		
			The undersigned beneficial owner of common stock (the “Registrable Securities”) of ReShape Lifesciences Inc., a Delaware corporation (the “Company”), understands that the Company has filed or intends to file with the Securities and Exchange Commission (the “Commission”) a registration statement (the “Registration Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement (the “Registration Rights Agreement”) to which this document is annexed. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.
		

		
			 
		

		
			Certain legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly, holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.
		

		
			 
		

		
			NOTICE
		

		
			 
		

		
			The undersigned beneficial owner (the “Selling Stockholder”) of Registrable Securities hereby elects to include the Registrable Securities owned by it in the Registration Statement.
		

		
			 
		

		
			The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:
		

		
			 
		

		
			QUESTIONNAIRE
		

		
			 
		

			
					
						1.

					
					
						Name.

				

		
			 
		

			
					
						 

					
					
						(a)

					
					
						Full Legal Name of Selling Stockholder

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				

		
			 
		

		
			 
		

			
					
						 

					
					
						(b)

					
					
						Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				

		
			i
		

		
			   
		

		
			

		 

		

			 

		

		

		
			   
		

		
			 
		

		
			 
		

			
					
						 

					
					
						(c)

					
					
						Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by this Questionnaire):

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				

		
			 
		

		
			2. Address for Notices to Selling Stockholder:
		

		
			 
		

			
					
						 

				
	
					
						 

				
	
					
						 

				
	
					
						Telephone:

					
					
						 

				
	
					
						Fax:

					
					
						 

				
	
					
						Contact Person:

					
					
						 

				

		
			 
		

		
			3. Broker-Dealer Status:
		

		
			 
		

			
					
						 

					
					
						(a)

					
					
						Are you a broker-dealer?

				

		
			 
		

		
			Yes ☐                           No ☐
		

		
			 
		

			
					
						 

					
					
						(b)

					
					
						If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?

				

		
			 
		

		
			Yes ☐                           No ☐
		

		
			 
		

			
					
						 

					
					
						Note:

					
					
						If “no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

				

		
			 
		

		
			 
		

			
					
						 

					
					
						(c)

					
					
						Are you an affiliate of a broker-dealer?

				

		
			 
		

		
			Yes ☐                           No ☐
		

		
			 
		

			
					
						 

					
					
						(d)

					
					
						If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?

				

		
			 
		

		
			Yes ☐                           No ☐
		

		
			 
		

		

		 

		

			 

		

	
					
						

					
						 

					
					
						Note:

					
					
						If “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

				

		
			ii
		

		
			   
		

		
			   
		

		
			 
		

		
			4. Beneficial Ownership of Securities of the Company Owned by the Selling Stockholder.
		

		
			 
		

			
					
						 

					
					
						Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable pursuant to the Purchase Agreement.

				

		
			 
		

			
					
						 

					
					
						(a)

					
					
						Type and Amount of other securities beneficially owned by the Selling Stockholder:

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				

		
			 
		

		
			 
		

		
			5. Relationships with the Company:
		

		
			 
		

			
					
						 

					
					
						Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.

				

		
			 
		

			
					
						 

					
					
						State any exceptions here:

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				

		
			 
		

		
			 
		

		
			 
		

		
			The undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.
		

		
			 
		

		
			By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.
		

		
			 
		

		
			

		 

		

			 

		

		

		
			IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent.
		

		
			 
		

			
					
						Date:

					
					
						 

					
					
						 

					
					
						Beneficial Owner:

					
					
						 

				

		
			 
		

		
			iii
		

		
			   
		

		
			   
		

			
					
						 

					
					
						By: 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Name: 

				
	
					
						 

					
					
						 

					
					
						Title: 

				

		
			        
		

		
			PLEASE SEND A COPY (OR EMAIL A .PDF COPY) OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE TO:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}]]